

# Glycosylphosphatidylinositols in Malaria Pathogenesis and Immunity: Potential for Therapeutic Inhibition and Vaccination

C. S. Boutlis<sup>1,2</sup> (✉) · E. M. Riley<sup>3</sup> · N. M. Anstey<sup>1,2</sup> · J. B. de Souza<sup>3,4</sup>

<sup>1</sup>International Health Program, Infectious Diseases Division, Menzies School of Health Research, P.O. Box 41096, 0811 Casuarina, NT, Australia  
[craig.boutlis@menzies.edu.au](mailto:craig.boutlis@menzies.edu.au)

<sup>2</sup>Charles Darwin University, 0909 Darwin, NT, Australia

<sup>3</sup>Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK

<sup>4</sup>Department of Immunology and Molecular Pathology, Royal Free and University College London Medical School, Windeyer Institute of Medical Research, 46 Cleveland Street, London W1T 4JF, UK

1	<b>Introduction</b> . . . . .	146
2	<b>The Toxic Basis of Malaria</b> . . . . .	147
2.1	The Toxic Paradigm in Malaria . . . . .	147
2.2	Structure of <i>P. falciparum</i> GPIs . . . . .	149
2.3	Biosynthesis of <i>P. falciparum</i> GPIs . . . . .	151
2.4	Specific Roles of <i>P. falciparum</i> GPIs in Malaria Pathogenesis . . . . .	152
2.5	Putative Malaria Toxins Other than GPI . . . . .	155
2.6	Summary . . . . .	157
3	<b>The Nature of Anti-toxic Immunity to Malaria</b> . . . . .	157
3.1	Tolerance of Malaria Parasitaemia Without Symptoms . . . . .	158
3.2	Limitation of Malaria Severity in the Face of Disease . . . . .	159
3.3	Summary . . . . .	161
4	<b>Immunity to <i>P. falciparum</i> GPIs</b> . . . . .	161
4.1	GPI Induction of Tolerance-Like Immunity . . . . .	162
4.2	Anti-GPI Antibodies in Human Malaria . . . . .	163
4.3	Antigen Recognition and Processing of GPIs . . . . .	165
5	<b>Potential for Therapeutic Inhibition of <i>P. falciparum</i> GPI Biosynthesis</b> . .	168
6	<b>Prospects for Anti-GPI Vaccination</b> . . . . .	170
7	<b>Conclusion</b> . . . . .	171
	<b>References</b> . . . . .	172

**Abstract** Glycosylphosphatidylinositols (GPIs) are found in the outer cell membranes of all eukaryotes. GPIs anchor a diverse range of proteins to the surface of *Plasmodium falciparum*, but may also exist free of protein attachment. In vitro and in vivo studies have established GPIs as likely candidate toxins in malaria, consistent with the prevailing paradigm that attributes induction of inflammatory cytokines, fever and other pathology to parasite toxins released when schizonts rupture. Although evolutionarily conserved, sufficient structural differences appear to exist that impart upon plasmodial GPIs the ability to activate second messengers in mammalian cells and elicit immune responses. In populations exposed to *P. falciparum*, the antibody response to purified GPIs is characterised by a predominance of immunoglobulin (Ig)G over IgM and an increase in the prevalence, level and persistence of responses with increasing age. It remains unclear, however, if these antibodies or other cellular responses to GPIs mediate anti-toxic immunity in humans; anti-toxic immunity may comprise either reduction in the severity of disease or maintenance of the malaria-tolerant state (i.e. persistent asymptomatic parasitaemia). *P. falciparum* GPIs are potentially amenable to specific therapeutic inhibition and vaccination; more needs to be known about their dual roles in malaria pathogenesis and protection for these strategies to succeed.

#### Abbreviations

GPI	Glycosylphosphatidylinositol
ICAM	Intercellular adhesion molecule
IFN	Interferon
Ig	Immunoglobulin
IL	Interleukin
LPS	Lipopolysaccharide
LT	Lymphotoxin
Man4	Fourth mannose
MHC	Major histocompatibility complex
MSP	Merozoite surface protein
NF	Nuclear factor
NO	Nitric oxide
PKC	Protein kinase C
PTK	Protein tyrosine kinase
TGF	Transforming growth factor
TLR	Toll-like receptor
TNF	Tumour necrosis factor

## 1

### Introduction

*Plasmodium falciparum* glycosylphosphatidylinositols (GPIs) became the focus of mainstream media attention in 2002 with the publication in *Nature* of a report demonstrating proof of concept for an anti-toxic vaccine that delayed malaria mortality in a rodent model (Schofield et al. 2002). As the best

characterised of the putative malaria toxins, interest in GPIs has burgeoned since the early 1990s to the point that strategies for creating fully synthetic GPI analogues are advancing rapidly (Lu et al. 2004; Liu and Seeberger 2004; Seeberger et al. 2004). This should soon enable investigators to clarify the role of GPIs in malaria pathogenesis and immunity. Understanding the potential for anti-GPI therapeutics and vaccination in human malaria requires an understanding of the pathophysiology of toxin-mediated events, as well as the nature of human anti-toxic immune responses. The conceptual framework must account for epidemiological phenomena that have been patiently catalogued by malariologists and withstood years of observation. Thus, the present review comprises three main parts: an outline of the toxic basis of malaria disease, with an emphasis on the proposed role of GPIs; a summary of what is thought clinically to represent anti-toxic immunity to malaria; and a discussion of what is presently known about immune responses to plasmodial GPIs.

## 2

### **The Toxic Basis of Malaria**

Fever and anaemia are common to all forms of human malaria, whereas severe malaria due to *P. falciparum* is additionally characterised by metabolic acidosis, hypoglycaemia, uraemia, pulmonary oedema and/or coma (referred to as cerebral malaria). These features of malaria pathogenesis are thought to result from a number of mechanisms acting in concert: destruction of red blood cells by the parasite, a cell-mediated inflammatory host response, and in the case of *P. falciparum* only, cytoadherence of parasitised erythrocytes to vascular endothelium. Cytoadherence in particular may lead to sequestration of parasites away from the general circulation and localised organ-based immunopathology. This section will focus on the potential roles played by parasite toxin(s) in initiating and/or exacerbating these key events. Readers seeking more information are referred to comprehensive recent reviews (Clark and Cowden 2003; Clark et al. 2004; Maitland and Marsh 2004).

### 2.1

#### **The Toxic Paradigm in Malaria**

A prevailing view of malaria pathogenesis can be stated as follows: that a parasite toxin (or toxins) induces production of host-derived inflammatory cytokines that are directly responsible for the characteristic febrile paroxysms of malaria, and indirectly contribute to other clinical manifestations. The Italian

Nobel laureate Camillo Golgi first established that paroxysms occurred following malarial shizogony in 1886 (Golgi 1886), but it took another 100 years for the physiological basis of this observation to be elucidated. Parallel lines of research converged in the late 1970s and early 1980s, leading to the recognition that endotoxin-mediated bacterial sepsis and malaria shared striking similarities in their pathophysiological features and cytokine profiles (Clark 1978; Clark et al. 1981). Central to this was the discovery and definition of tumour necrosis factor (TNF)- $\alpha$ , followed by recognition that it mediated pathology in rodent malaria models (Clark et al. 1987) and could be induced by malaria parasites and putative malaria toxins in vitro (Kwiatkowski et al. 1989; Scragg et al. 1999). Subsequently, plasma TNF- $\alpha$  levels were shown to correlate with the severity of human malaria (Grau et al. 1989; Kern et al. 1989), and a causal role was suggested by genetic association studies linking polymorphisms in the TNF- $\alpha$  promoter region to disease outcome (McGuire et al. 1994; Wattavidanage et al. 1999; Aidoo et al. 2001).

With time, it has become clear that TNF- $\alpha$  is but one in a milieu of soluble mediators that together influence the pathophysiology of malaria. Monoclonal anti-TNF- $\alpha$  antibodies given to Gambian children with cerebral malaria reduced fever (Kwiatkowski et al. 1993) but had no effect on mortality in a subsequent randomised placebo-controlled trial (van Hensbroek et al. 1996). Similarly disappointing results were observed using polyclonal anti-TNF- $\alpha$  antibodies in Thai adults with severe malaria (Looareesuwan et al. 1999), and the relevance of TNF- $\alpha$  polymorphisms has since been questioned (Bayley et al. 2004). Recent studies have demonstrated that lymphotoxin (LT)- $\alpha$  (formerly TNF- $\beta$ ), rather than TNF- $\alpha$ , appears to be the principle mediator of murine cerebral malaria in the *P. berghei* (ANKA) model (Engwerda et al. 2002; Rae et al. 2004). Interestingly, this is consistent with research conducted 10 years earlier that showed elevated levels of LT- $\alpha$  in human malaria, and induction of interleukin (IL)-6 and hypoglycaemia in mice injected with the cytokine (Clark et al. 1992). Together, these studies highlight that the pivotal role ascribed to TNF- $\alpha$  in malaria pathogenesis may in part have reflected its study in isolation from the complex interplay of other mediators (Dodoo et al. 2002). Evidence from in vitro, animal and human studies (reviewed by Artavanis-Tsakonas et al. 2003; Clark et al. 2004) suggests that at least the following are also involved in determining the outcome of malaria infection: interferon (IFN)- $\gamma$ , IL-1, 6, 10, 12 (Dodoo et al. 2002), and 18 (Singh et al. 2002), transforming growth factor (TGF)- $\beta$  (Omer and Riley 1998), chemokines, nitric oxide (NO) (Anstey et al. 1996; Hobbs et al. 2002) and prostaglandins (Perkins et al. 2001). Moreover, in different settings or at different levels, the same cytokine or mediator may be harmful or protective (reviewed by Hunt and Grau 2003). By way of example, TNF- $\alpha$  itself has been ascribed a protective


role in regulating parasite density (Kwiatkowski 1995), which is supported by the demonstration of a parasitocidal effect of TNF- $\alpha$  on *P. falciparum* in vitro (Muniz-Junqueira et al. 2001).

It is generally thought that the soluble mediators induced by malaria toxins contribute not only to fever, but also to the end-organ, metabolic and haematological consequences of disease. TNF- $\alpha$  and LT- $\alpha$  have been shown to increase expression of parasitised erythrocyte receptors such as intercellular adhesion molecule (ICAM)-1 on endothelial cells (Ockenhouse et al. 1992; Engwerda et al. 2002), thus potentially initiating a vicious cycle that may lead to severe malaria by sequestering more parasitised cells and further increasing local cytokine production. Other mediators, such as NO and prostaglandins, decrease cytokine-induced endothelial ICAM-1 and reduce cytoadherence of parasitised erythrocytes (Xiao et al. 1999; Serirom et al. 2003). Other factors are likely to contribute to protection or pathology in CM, including IFN- $\gamma$ , migration inhibitory factor (Clark et al. 2003b), carbon monoxide (Clark et al. 2003a) and chemokines. The degree of anaemia in malaria is thought to exceed that which can be explained by destruction of parasitised erythrocytes alone, leading to the proposition that erythropoiesis may be depressed by soluble mediators (reviewed by Menendez et al. 2000). Severe metabolic acidosis with hyper-lactataemia is associated with a very high mortality in malaria (English et al. 1996) and probably results from a combination of tissue hypoxia, direct effects of cytokines, lactate production by parasites, and decreased clearance of lactate by the liver (Marsh and Snow 1997). The pathogenesis of other metabolic derangements such as hypoglycaemia may share similar antecedents (Clark et al. 1997).

## 2.2

### Structure of *P. falciparum* GPIs

GPI molecules are evolutionarily conserved glycolipids present in the outer membranes of eukaryotic cells. Their core structure comprises a single membrane-associated phospholipid head, attached linearly to an inositol ring that is followed by a tetrasaccharide containing one glucosamine and three sequentially numbered mannose residues (Fig. 1). A phosphoethanolamine group attached to the terminal mannose affords stable anchorage for a diverse range of proteins. GPIs vary between eukaryotes in a limited number of ways that nonetheless appear to impart a wide range of functional differences. In mammals and yeast, an additional ethanolamine phosphate is invariably present as a side-chain on the first mannose and occasionally on the second mannose. Protozoa such as *Trypanosoma brucei* may carry an additional carbohydrate modification on the first mannose (Ferguson 1999). In contrast,



**Fig. 1** Schematic representation of *P. falciparum* GPI. The lipid moieties are incorporated into the plasma membrane and joined via glycerol and phosphate (P) to an inositol ring. A conserved core glycan chain composed of glucosamine and three mannose residues is attached at the inositol 6 position. The terminal third conserved mannose residue is joined via a P ester to ethanolamine, which facilitates linkage to the C-terminus of a protein via an amide group. *P. falciparum* GPI remains acylated at the inositol 2-position, and a fourth side-chain mannose is typically attached to the ethanolamine-linked mannose

no side-chain modifications of the first two mannose residues have been described in *P. falciparum*. A side-chain fourth mannose (Man<sub>4</sub>) is typically attached to the terminal mannose in *P. falciparum* and yeast, whereas this was thought to be uncommon until recently in mammals. It has now been demonstrated that *hSMP3* is the human homologue for yeast *SMP3*, and that it encodes the mannosyltransferase responsible for addition of Man<sub>4</sub> to GPIs (Taron et al. 2004). Although the gene is only weakly expressed in many cultured mammalian cell lines, it is expressed in most human tissues, challenging the previous paradigm that Man<sub>4</sub>-GPI formation is relatively unimportant in mammalia.

Mammalian GPI inositol rings may be acylated by palmitate in some cases, although it is common for mammalian inositol to be deacylated following GPI biosynthesis (Chen et al. 1998). In contrast, *P. falciparum* inositol remains acylated, most often with palmitate (90%) but occasionally with myristate (10%) (Naik et al. 2000a). The phosphorylated lipid moiety attached to inositol in *P. falciparum* is invariably diacylglycerol in structure (Naik et al. 2000a), but in mammalian cells is predominantly 1-alkyl, 2-acyl glycerol. Recent

examination by gas chromatography-mass spectrometry of protein-anchored “major” GPIs in *P. falciparum* has demonstrated heterogeneity resulting in at least five different structures, which can be fully ascribed to compositional differences in the fatty acyl substituents (Naik et al. 2000a). Importantly, variation in lipid composition did not appear to influence the likelihood of protein anchoring by the GPIs and it is likely that other biologically active “minor” GPIs with unusual fatty acyl substituents remain to be described (Naik et al. 2000a). Plasmodial GPIs from human and rodent malaria species demonstrate a high level of conservation in structure (Gerold et al. 1997; Naik et al. 2000a; Kimmel et al. 2003), which is also seen in widely dispersed geographical isolates of *P. falciparum* (Berhe et al. 1999). To date, GPIs have not been described in other species of plasmodia that cause malaria in humans.

### 2.3

#### **Biosynthesis of *P. falciparum* GPIs**

The general processes involved in GPI biosynthesis have been comprehensively reviewed (Ferguson 1999; Kinoshita and Inoue 2000; Eisenhaber et al. 2003) and will be only briefly summarised here. GPIs are assembled sequentially in the endoplasmic reticulum by a number of proteins/protein complexes that exhibit a variety of catalytic and regulatory roles. These proteins and their genes are well characterised in mammals, and this has enabled matching of sequence homologues in other eukaryotes in a number of instances through database mining. Homologues have been identified in *P. falciparum* for 8 of the approximately 20 known protein components of human GPI biosynthesis, with a 40%–70% similarity in amino acid sequences (Delorenzi et al. 2002; Shams-Eldin et al. 2002). The existence of other homologues may have been concealed by the level of stringency used for database matching or incomplete annotation of the *P. falciparum* genome at the time; also, non-homologous proteins may perform some of the designated functions (Delorenzi et al. 2002). In general, the *P. falciparum* homologues described are for proteins involved in key catalytic roles, rather than in regulating the rate or stability of reactions. Consistent with the proposed structure of *P. falciparum* GPIs, homologues for the mammalian genes that encoded addition of phosphoethanolamine groups to non-terminal mannoses and deacylation of inositol (which appears not to occur in *P. falciparum*) were not found. It has been suggested that this overall economy may have arisen through an adaptation to rapid growth and from lesser requirements for fine tuning compared to higher eukaryotes (Delorenzi et al. 2002).

The transamidation reaction that covalently anchors proteins to GPI inside the endoplasmic reticulum depends on recognition of a signal sequence and

proteolytic cleavage of a carboxy-terminal pro-peptide (Eisenhaber et al. 2003). This process appears to be intricately mediated in mammalian cells by the protein PIG-T, which possesses both a hook for the key catalytic subunit (PIG-K) and a hole-like beta propeller structure that regulates access of C terminal oligopeptides to the protease site through a tunnel (Eisenhaber et al. 2003). A similar coding region for the *PIG-T* gene was found in *P. falciparum*, but failed stringency tests (Delorenzi et al. 2002). However, it has been noted that sequence similarity BLAST searching may fail to detect *PIG-T* homologues, unless consideration is given to secondary structural preferences or physical property patterns (Eisenhaber et al. 2003). As cells from mammals and parasitic protozoa appear to differ in their preference for particular amino acid coding regions in the signal sequence (Moran and Caras 1994), the transamidation reaction represents a particularly attractive target for species-specific inhibitors.

## 2.4

### Specific Roles of *P. falciparum* GPIs in Malaria Pathogenesis

A range of in vitro and in vivo animal studies have demonstrated that purified *P. falciparum* GPIs can induce the pathophysiology ascribed to putative malaria toxins and/or that anti-GPI antibodies can neutralise these effects. Mouse macrophages were first shown to produce TNF- $\alpha$  after incubation with erythrocytes parasitised with either *P. yoelii* or *P. berghei* in vitro in 1988 (Bate et al. 1988). Consistent results were soon demonstrated for human monocytes in the presence of *P. falciparum* in vitro (Kwiatkowski et al. 1989). This was followed by partial characterisation of the likely toxin using physical and chemical extraction procedures (Bate et al. 1992b) coupled with monoclonal and polyclonal antibody neutralisation studies (Bate et al. 1992a; Bate and Kwiatkowski 1994a). By 1993, it was clear that the putative toxin was a GPI and that its injection into thioglycollate-primed rodents could reproduce major features of acute clinical malaria, including pyrexia and hypoglycaemia (Schofield and Hackett 1993); similar findings have subsequently been reported in unprimed mice (Elased et al. 2004). Concurrently, it was shown that a monoclonal antibody to *P. falciparum*-derived GPIs could neutralise the TNF- $\alpha$ -inducing activity of whole-parasite extracts in vitro (Schofield et al. 1993), suggesting that GPIs alone may be responsible for TNF- $\alpha$  induction. Polyclonal antibodies raised in T-cell-deficient mice (Bate et al. 1990) and sera from human patients infected with both *P. falciparum* and *P. vivax* (Bate and Kwiatkowski 1994b) were reported to have similar activity. However, we have been unable to confirm this ourselves, with toxin-neutralisation assays showing no clear-cut correlation between anti-GPI an-



tibody titres in serum and the ability of purified immunoglobulin (Ig)G from the same serum to neutralise TNF- $\alpha$  induction by whole-parasite extracts from a macrophage cell line in vitro (J.B. de Souza et al., unpublished data). These data suggest either that GPI is not the only TNF-inducing component of parasite extracts or that not all anti-GPI antibodies are able to neutralise GPI activity.

By the mid-1990s, *P. falciparum* GPIs had been shown capable of inducing macrophage production of IL-1 (Schofield and Hackett 1993) as well as production of NO by macrophages and vascular endothelial cells in a process enhanced by IFN- $\gamma$  (Tachado et al. 1996). *P. falciparum* GPIs were then shown to increase endothelial cell expression of ICAM-1, vascular cell adhesion molecule-1 and E-selectin (receptors implicated in cytoadherence of parasitised erythrocytes) in a process enhanced by TNF- $\alpha$  and IL-1 (Schofield et al. 1996). This process was also blocked by monoclonal anti-GPI antibodies. Consistent with the ability to induce hypoglycaemia in mice, *P. falciparum* GPIs were shown to possess insulin-mimetic activity through increasing glucose oxidation in murine adipocytes in vitro (Schofield and Hackett 1993). The culmination of these studies was the recent demonstration that murine antibodies raised through vaccination with a *P. falciparum* GPI glycan analogue completely abolished whole schizont extract-induced TNF- $\alpha$  release from mouse macrophages (Schofield et al. 2002). To the extent that the in vitro model matches the clinical situation in humans, this is the most suggestive evidence to date that GPIs are the predominant pro-inflammatory toxins of *P. falciparum*.

It has not yet been determined precisely how *P. falciparum* GPIs initiate the intracellular signalling that results in expression of cytokines, NO and adhesion molecules. Early studies using specific inhibitors supported a two-step model of cellular activation that ultimately ends with activation of the transcription factor nuclear factor (NF)- $\kappa$ B (Schofield et al. 1996; Tachado et al. 1996, 1997; Vijaykumar et al. 2001); the first signal provided by the glycan moiety [activating protein tyrosine kinase (PTK)] and the second by the diacylglycerol [activating protein kinase C (PKC)]. The issue of whether the two signals require insertion and/or endocytosis of whole GPIs or GPI substructures into the plasma membrane (Vijaykumar et al. 2001) or can be provided entirely extracellularly (Vijaykumar et al. 2001) remains unresolved. More recently it has been suggested that *P. falciparum* GPIs can initiate intracellular signalling—without internalisation—through toll-like receptors (TLRs), although the extent to which signalling via the PTK, PKC and TLR pathways may overlap is still unclear. In vitro studies examining TNF- $\alpha$  production by GPI-stimulated macrophages derived from the bone marrow of TLR knockout mice have demonstrated a major role for TLR2, a lesser role

for TLR4, and a potential minor role for other pathways not dependent on the TLR2/TLR4 shared adapter protein MyD88 (Krishnegowda et al. 2004). Similar results were apparent in experiments using human monocytes that were pre-treated with monoclonal antibodies to TLR2 and/or TLR4. Subsequent intracellular signalling in both the mouse and human cells involved activation of a number of second messengers, including ERK1/ERK2, JNK and p38, and ultimately the NF- $\kappa$ B pathway. Parallel experiments by the same investigators demonstrated that the pattern of TNF- $\alpha$ , IL-6, IL-12 and NO production by GPI-stimulated mouse macrophages depended on differential activation of these signalling molecules and a variable requirement for co-stimulation with IFN- $\gamma$  (Zhu et al. 2004). This may have relevance in vivo, as it has previously been shown that CD3<sup>+</sup> T cells are required for optimal TNF- $\alpha$  production by human monocytes stimulated by *P. falciparum* ex vivo (Scragg et al. 1999), which may also indicate the involvement of IFN- $\gamma$  (reviewed by Artavanis-Tsakonas et al. 2003).

The exact structural requirements of *P. falciparum* GPIs for activation of intracellular signalling also require further clarification. The issue of whether glycan-induced signalling is dependent on the third (Tachado et al. 1997) or fourth terminal (Vijaykumar et al. 2001) mannose appears to have been resolved in favour of the former, with Man<sub>3</sub> GPIs shown to possess approximately 80% of the TNF- $\alpha$ -inducing activity of Man<sub>4</sub> GPIs (Krishnegowda et al. 2004). Insolubility of Man<sub>3</sub> GPIs in the solvent (80% ethanol) used for transfer from the stock vial to the culture medium is now thought to explain the previous results (Vijaykumar et al. 2001). More in keeping with their previous findings (Vijaykumar et al. 2001), diacylated *sn*-2 *lyso*-GPIs (resulting from partial deacylation of native GPIs by phospholipase A<sub>2</sub>) induced levels of TNF- $\alpha$  from mouse macrophages and human monocytes that were similar to those from the intact molecules (Krishnegowda et al. 2004). Interestingly, heterodimerisation of TLR2 (a basic requirement for TLR2-induced signalling) involved TLR1 in the case of triacylated GPIs but TLR6 for the diacylated *sn*-2 *lyso*-GPIs, thus implicating lipid composition as a basis for antigenic discrimination by macrophages—a phenomenon that the authors point out has a precedent in the case of bacterial lipoproteins (Takeda et al. 2002; Akira and Hemmi 2003). Just as intriguing was the finding that GPIs were degraded and inactivated in the presence of mouse macrophages and human monocytes, consistent with cell-surface related activity of phospholipase A<sub>2</sub> and phospholipase D (Krishnegowda et al. 2004). To what extent human monocyte phospholipases may be able to regulate the activity of *P. falciparum* GPIs in vivo, and whether this may further be influenced by phospholipases released into serum during human malaria (Vadas et al. 1993), remains to be determined.

In addition to their putative roles as toxins, GPIs may indirectly contribute to malaria pathogenesis both by anchoring protein determinants of parasite virulence and altering their pathological and immune functions. In *P. falciparum*, as in all eukaryotes, the fundamental physiological role of GPIs is to stably anchor a diverse range of proteins on cellular plasma membranes. A number of important proteins appear to be GPI-anchored in *P. falciparum*, including merozoite surface protein (MSP)-1, MSP-2 and MSP-4 (Chatterjee and Mayor 2001; Gowda 2002). In addition, a large pool of *P. falciparum* GPIs exist free of protein attachment (Gerold et al. 1994), which is also common in other parasitic protozoa (Ropert and Gazzinelli 2000). It is possible, although not yet proven, that it is the free GPIs released at the time of schizont rupture that are predominantly responsible for toxin-mediated effects. It has been reported that the presence of GPI anchors on sporozoite protein vaccines impairs the development of antibody (Martinez et al. 2000; Scheiblhofer et al. 2001) and T-cell responses (Bruna-Romero et al. 2004) with consequent attenuation of vaccine-induced immunity; similar observations have been made in other systems (Wood and Elliott 1998). However, following DNA vaccination, antibody responses to a gametocyte-specific antigen are enhanced by the retention of the GPI anchor signal sequence (Fanning et al. 2003). These data suggest that the presence of glycans alters the solubility and membrane interactions of proteins, and thus the pathway of protein trafficking within an antigen-presenting cell. Additionally, GPI attachment may alter the conformation of anchored proteins in a manner that influences the proteins' function and/or immunogenicity. These observations may have important implications for the development of recombinant protein vaccines, many of which are based on GPI-anchored proteins (reviewed by Gowda 2002).

## 2.5

### Putative Malaria Toxins Other than GPI

In addition to GPI, haemozoin (or "malaria pigment"; an insoluble digestion product of trophozoites comprising detoxified haemoglobin, as well as remnants of host and parasite membranes) has been implicated as a malaria toxin (Arese and Schwarzer 1997). Purified and synthetic haemozoin ( $\beta$ -haematin) were linked to inflammatory cytokine production *in vitro* in a number of studies (Pichyangkul et al. 1994; Prada et al. 1995; Sherry et al. 1995; Mordmuller et al. 1998) conducted in the period preceding identification of *Mycoplasma* contamination of parasite cultures (Turrini et al. 1997; Rowe et al. 1998). Subsequently, de-proteinated haemozoin enriched from *P. falciparum* culture was shown to induce TNF- $\alpha$  and IL-1 $\beta$  production by human peripheral blood mononuclear cells *ex vivo*, which was able to be blocked by naturally occur-

ring IgM antibodies (Biswas et al. 2001). More recently, it was demonstrated that synthetic haemozoin induced inflammatory cytokines (including IL1- $\alpha$ , IL1- $\beta$ , IL-6, and IL-12), chemokines and their receptors, and migration of neutrophils and monocytes, following injection into mice (Jaramillo et al. 2004). Unlike the case with GPIs, it appears that *P. falciparum* haemozoin is more likely to activate host cells through a hitherto unique TLR9-mediated, MyD88-dependent pathway that is sensitive to inhibition by chloroquine (Pichyangkul et al. 2004; Coban et al. 2005). In addition to induction of soluble mediators, haemozoin-laden macrophages have been shown to produce large quantities of the free fatty acids 12- and 15-hydroxy-arachidonic acid, which may be pathogenic by causing vascular damage and increased cytoadherence (Schwarzer et al. 2003).

Others have shown that *P. falciparum*-derived haemozoin induced NO synthase-2 expression in cultured human blood monocytes *ex vivo*, which was more pronounced in cells from children with anaemia (Keller et al. 2004). A similar effect has been shown in mouse macrophages with *P. falciparum*-derived and synthetic haemozoin, although a requirement for co-stimulation with IFN- $\gamma$  was apparent in that study (Jaramillo et al. 2003). In contrast,  $\beta$ -haematin was shown to suppress TNF- $\alpha$  and NO production by lipopolysaccharide (LPS)-stimulated mouse macrophages (Taramelli et al. 1995); an effect later attributed to  $\beta$ -haematin-induced oxidative stress (Taramelli et al. 2000). Another study showed that high levels of haemozoin ingestion by intervillous blood monocytes were associated with suppression of TNF- $\alpha$ , prostaglandin- $E_2$  and IL-10 in women with placental parasitaemia (Perkins et al. 2003). The source of mononuclear cells in these different studies, and the nature of the interactions between the cells and haemozoin, may be factors to consider in resolving these apparent contradictions (Basilico et al. 2003; Jaramillo et al. 2005).

Other candidates for "malaria toxins" are anti-malarial IgE-antigen complexes and IgE-anti-IgE complexes, which may also induce TNF- $\alpha$  release from peripheral blood mononuclear cells *in vitro* (Perlmann et al. 1997). These complexes have been proposed to activate NF- $\kappa$ B transcription factors by cross-linking the macrophage low-affinity Fc $\epsilon$  receptor for IgE (Perlmann et al. 1997). Using an *in vitro* toxin-neutralisation assay, which measures TNF- $\alpha$  in supernatants of cultured macrophages incubated with malaria-immune sera and *P. falciparum* schizont lysates, we have shown that some malaria-immune sera themselves induce TNF- $\alpha$  in the absence of exogenous malaria antigen; this activity is absent from purified IgG (J.B. de Souza et al., unpublished data). Although this might be explained by trace amounts of GPI in the serum (as the sera were taken from residents of highly malaria-endemic areas), it is possible that serum IgE complexes induce TNF- $\alpha$ ; this notion is fur-

ther supported by the observation that non-IgG antibodies in other malaria-immune sera synergise with parasite extract to enhance TNF- $\alpha$  production (J.B. de Souza et al., unpublished data). These data are consistent with the likely involvement of an immune complex-mediated TNF- $\alpha$  triggering pathway. Anti-malarial IgE/antigen complexes may exert pathogenic effects by depositing on cerebral microvasculature (Maeno et al. 2000), leading to local induction of pro-inflammatory cytokines, with consequent vascular damage. This would explain the recent finding that West African children with severe malaria had higher anti-*P. falciparum* IgE levels than age-matched children with mild malaria (Calissano et al. 2003).

## 2.6

### Summary

It should be recognised that, at present, the evidence that *P. falciparum* GPIs act as toxins in humans in vivo is circumstantial. Purified or synthetic GPIs have not been injected into humans, and nor have anti-GPI antibodies been shown to inhibit the pathogenesis of *P. falciparum* in vivo; thus, the level of evidence is less than that associating bacterial endotoxin with the clinical manifestations of sepsis. Regardless, in vitro studies and data from animal models of malaria have identified clear avenues of investigation into the role of GPIs in human malaria, as well as other putative toxins such as haemozoin and IgE complexes.

## 3

### The Nature of Anti-toxic Immunity to Malaria

Bewilderment regarding the mechanisms of anti-malarial immunity is reflected by the number of terms used to describe it; among others, natural, clinical, innate, acquired, specific, non-specific, anti-parasitic, anti-disease, anti-toxic, cell-mediated, antibody-mediated, tolerance, premunition and semi-immune. In part, confusion in the use of these terms (sometimes interchangeably) has arisen through a desire to explain observable epidemiological phenomena on the one hand, within the confines of existing immunological paradigms on the other. As the focus of this review is the putative malaria toxin GPI, and immune responses to it, we will generally refer to anti-toxic immune responses, and dispense with the commonly used epithet “anti-disease”, as the latter may be considered the *sine qua non* of all forms of immunity. Hence, this section concerns differences in the clinical condition that can reasonably be expected to infer the existence of anti-toxic immunity, which may in theory act by inhibition of parasite metabolic pathways leading to reduced or

defective toxin production (of which little is presently known), neutralisation of toxin at or shortly after the time of release, interference with the cellular mechanisms triggered by toxin activation that lead to production of inflammatory mediators, and/or diminished host responsiveness to one or more of the inflammatory processes that follow.

### 3.1

#### **Tolerance of Malaria Parasitaemia Without Symptoms**

Despite thousands of publications related to anti-malarial immunity, it is probably just as true to say today as it was 100 years ago that the best correlate of immunity to malaria is the presence of malaria parasites in the blood of individuals without symptoms (Sinton 1938; McGregor et al. 1956). It is generally accepted that the likelihood of observing asymptomatic parasitaemia within a population correlates with the intensity of exposure, and that it is unlikely to be observed in previously malaria-naïve individuals. It has been shown by some that asymptomatic infections can become established and persist at reasonably stable densities over time (Sowunmi 1995; Farnert et al. 1997; Smith et al. 1999; Bruce et al. 2000), but others have challenged this notion in longitudinal studies demonstrating an increased future risk of symptoms (Missinou et al. 2003; Njama-Meya et al. 2004). It is evident though, from our own studies in regions of intense malaria transmission, that a high prevalence of asymptomatic infections can be expected in individuals of all ages in whom signs and symptoms are objectively evaluated on multiple occasions over 24 h (Boutlis et al. 2002, 2003b). The levels of parasitaemia observed, especially in children (Rogier et al. 1996; Boutlis et al. 2002), are often much higher than those recorded to cause disease in previously malaria-naïve subjects (Gatton and Cheng 2002; Molineaux et al. 2002). Given that it has long been assumed that malaria parasites release pyrogenic substances (i.e. toxins) during schizogony (Golgi 1886), and there is no evidence to suggest that field strains can become avirulent, it seems reasonable to suppose that host immune responses maintain the healthy phenotype during asymptomatic infection.

Through detailed epidemiological studies conducted in regions of high malaria endemicity, it has been observed that young children will tolerate high levels of malaria parasitaemia; levels that are much more frequently associated with disease in adults (Smith et al. 1994; Rogier et al. 1996). By mathematical modelling, the risk of symptoms has been shown to correlate with the level of parasitaemia in an age-dependent manner, with a peak at approximately 1 year of age that declines steeply through early childhood to a plateau in adolescence (Smith et al. 1994; Rogier et al. 1996). The exponentially decaying curve that describes the relationship between the level of

parasitaemia associated with fever and increasing age has been referred to as defining a “pyrogenic threshold” (Rogier et al. 1996). These results were generally in keeping with observations such as those made by Miller in Liberia in 1958: “...while adults were more efficient in suppressing parasite levels and suffered less from clinical attacks of malaria, children could tolerate higher parasite burdens without showing clinical evidence of disease” (Miller 1958). In contrast, the application of mathematical modelling techniques in regions of low or unstable malaria transmission has shown a less discrete relationship between the level of parasitaemia and the risk of symptoms, with generally lower pyrogenic thresholds and less dependence on age (Prybylski et al. 1999; Boisier et al. 2002). This suggests that fully effective anti-toxic immunity may only become manifest in areas of quite high and/or stable malaria transmission. Interestingly, studies of experimental infection in previously malaria-naïve subjects have shown that an individual’s pyrogenic threshold may increase following an initial infection, as well as being influenced by host genetics and the “strain” of parasite (Gatton and Cheng 2002; Molineaux et al. 2002).

Considered together, these observations are consistent with a model in which repetitive and ongoing exposure to malaria infection results in relatively short-lived anti-toxic immune responses that abrogate inflammatory pathology. It is evident from studies in hyper-endemic regions that the efficacy of these responses is highest in early childhood and is lowest in adulthood. This creates an apparent paradox in relation to the fact that, in endemic areas, malaria severity is highest in young children and the frequency of malaria attacks reduces with age. This can be resolved, however, by conceptualising disease as resulting from uncontrolled expansion of parasite densities that overcome an individual’s pyrogenic threshold. The immune responses that act to limit parasite replication (sometimes referred to as “anti-parasitic” responses) appear to increase with age, in contrast to the anti-toxic responses that maintain tolerance of parasitaemia. The ability to limit the severity of disease in the face of unchecked parasite growth may be expected to result from a number of factors, some of which may be anti-toxic in nature (Sect. 3.2), but in addition may involve prevention of other critical events that are not primarily toxin-mediated, such as cytoadherence and anaemia.

### 3.2

#### **Limitation of Malaria Severity in the Face of Disease**

The model proposed in the previous section is broadly consistent with the concept that anti-malarial immune responses can be categorised as anti-parasitic, anti-fever (i.e. parasite tolerance), and anti-severe disease (Snow



and Marsh 1998). The latter may involve mechanisms that reduce cytoadherence (e.g. antibodies to cytoadherence ligands on infected erythrocytes), whilst alterations in the balance of inflammatory and anti-inflammatory cytokines may effect both anti-fever and anti-severe disease immunity (Omer et al. 2000). To better understand the influence of age itself (separated from exposure) on malaria severity, Baird and colleagues have prospectively studied recently arrived Indonesian transmigrants from very low-endemic Java into hyper-endemic Papua Province (Baird 1998). Previously malaria-naïve children appeared to manifest relative resistance to the severity of malaria compared to adults (Baird et al. 1998). The explanation for these findings is not entirely clear, and results may have been biased in part by differences in the use of prophylaxis or in treatment-seeking behaviour in adults and children. Alternatively, it is plausible that children make lower levels of inflammatory cytokines in response to a given "dose" of parasites (Riley 1999).

Of the numerous candidate host responses proposed to limit malaria severity, some may be predominantly anti-toxic in nature, whereas others may act more broadly. For example, a growing body of literature (reviewed by Anstey et al. 1999a) suggests that genetic (Hobbs et al. 2002) and acquired influences regulating NO production act to reduce malaria severity through cross-talk with other soluble mediators, such as TNF- $\alpha$  (Iuvone et al. 1996) and prostaglandins (N.M. Anstey et al., unpublished data), in addition to reducing expression of endothelial cytoadherence receptors (Serirom et al. 2003). It had previously been suggested that individuals in malaria-endemic regions produced NO in an age-dependent manner that was correlated with the age-dependent pyrogenic threshold (Clark et al. 1996; Anstey et al. 1999b). However, a recent detailed longitudinal examination of NO production in malaria-exposed children and adults living in Madang, Papua New Guinea has shown that NO production differs little across age groups from age 2 to 60 years (Boutlis et al. 2004).

Additionally, the anti-inflammatory cytokines IL-10 and TGF- $\beta$  have repeatedly been shown to reduce the toxic effects of malaria infections in mice and in humans. The pathology of *P. chabaudi chabaudi* infection and the mortality in IL-10-deficient mice are ameliorated by anti-TNF- $\alpha$  and exacerbated by anti-TGF- $\beta$  antibodies (Omer and Riley 1998; Dodoo et al. 2002; Li et al. 2003), and recent data suggest an important role for regulatory T cells in setting the pro-inflammatory/anti-inflammatory cytokine balance (Omer et al. 2003; Hisaeda et al. 2004). Disentangling the influence of a raft of other cell-mediated and cytokine responses on malaria severity is difficult in isolation, but has recently been reviewed in the context of an overall model of anti-malarial immunity that also considers factors such as nutrition (Artavanis-Tsakonas et al. 2003). The subtlety and importance of cross-species interactions between



malaria and other infections, such as intestinal helminths, that may also influence cell-mediated phenomena, are beginning to be appreciated (Nacher 2002; Boutlis et al. 2003b; Le Hesran et al. 2004; Nacher 2005; Hesran 2005), but further discussion is beyond the scope of the present review.

### 3.3

#### Summary

It appears that anti-toxic immune responses to malaria may contribute to the maintenance of malarial tolerance on the one hand, while contributing to resistance to severe disease in those unable to limit exponential expansion of parasitaemia on the other. It should be recognised that the potential for multiple anti-toxic effector mechanisms exists, but that they do not necessarily have the same relationship with age. For example, those that mediate tolerance may decrease with age, whereas those underlying resistance to disease severity may increase, with some degree of overlap in the transition from one to another. While an individual's genetic make-up and parasite strain differences may contribute to the overall level of toxicity manifest in the host-parasite relationship, it is likely that the level of exposure to malaria and other infections, and factors related to age per se, are also involved. It seems logical that the sum of an individual's anti-toxic immune responses will act in concert to protect the individual by either neutralising the parasite toxin(s) and/or diminishing the host's response to toxin-triggered events. Furthermore, it is apparent that not all immune responses acting to reduce the severity of malaria need be thought of as being primarily anti-toxic in nature.

## 4

### Immunity to *P. falciparum* GPIs

Assuming that the preparations used were pure and free from contamination (Naik et al. 2000a), it has been consistently demonstrated in a number of studies done in malaria-endemic regions that GPIs purified from *P. falciparum* are recognised by human antibodies (Naik et al. 2000a; de Souza et al. 2002; Boutlis et al. 2002; Hudson Keenihan et al. 2003; Suguitan et al. 2004). This has raised the possibility that these naturally occurring antibodies could neutralise GPIs and influence the outcome of human malaria. The presence of antibodies implies that GPIs are recognised by immune cells; hence, GPIs may also potentially elicit other cellular immune responses that are not antibody-mediated. It is important to understand how GPIs may initiate these immune responses, and how they are effected, if vaccination against GPIs is to be used for protection against malaria.

#### 4.1

##### **GPI Induction of Tolerance-Like Immunity**

Obvious parallels exist between the phenomena of malarial tolerance and bacterial endotoxin tolerance, which has led to the proposition that they are mediated by common molecular pathways (Clark et al. 2004). The phenomenon of endotoxin tolerance was initially defined in the 1960s on the basis that rabbits could be effectively immunised with a low dose of bacterial endotoxin (LPS) against death from the subsequent injection of a potentially lethal dose (reviewed by West and Heagy 2002). Similarly, febrile responses in humans decrease with subsequent injections of endotoxin (van der Poll and van Deventer 1999). The tolerant state in animals was later shown to correlate with a reduction in TNF- $\alpha$  production in response to repeated endotoxin injection that persisted for several weeks (Sanchez-Cantu et al. 1989). Subsequently, it was shown that LPS-stimulated production of TNF- $\alpha$ , IL-1 $\beta$ , IL-6, and IL-10 in whole blood taken from human volunteers 3 h after an intravenous injection of *Escherichia coli* LPS was significantly reduced compared to baseline, but restored at 24 h (van der Poll et al. 1996). Further in vitro experiments using human and animal monocytes/macrophages defined the characteristic physiological changes accompanying repeated exposure to endotoxin: inhibition of TNF- $\alpha$ ; augmentation of NO and prostaglandin-E<sub>2</sub>; and variably altered IL-6, IL-1 and IL-8 secretion (West and Heagy 2002). Given the timescale of the induction of endotoxin tolerance, the simplest interpretation of these data is that cells become temporarily refractory to endotoxin after stimulation.

Optimal responses to LPS derived from *Enterobacteriaceae* depend on cellular recognition by TLR4 complexed with CD-14 and the membrane-associated molecule MD-2 (Latz et al. 2002). Binding of LPS leads to induction of protein kinases, which in turn activate nuclear factors including NF- $\kappa$ B (Ziegler-Heitbrock et al. 1994) that influence transcriptional activation of numerous inflammatory cytokine genes (Dobrovolskaia and Vogel 2002). Desensitised human monocytes rendered tolerant by pre-treatment with LPS accumulate an excess of functionally inactive NF- $\kappa$ B complexes comprising p50 homodimers (Ziegler-Heitbrock et al. 1994; Kastenbauer and Ziegler-Heitbrock 1999) and have elevated concentrations of the NF- $\kappa$ B-inhibitory protein I $\kappa$ -B $\alpha$  (Wahlstrom et al. 1999; Ferlito et al. 2001); the activation of other kinases in the signal transduction cascade is also inhibited in tolerant cells (West and Heagy 2002). Alternatively, although alteration of intracellular signal transduction pathways appears likely to mediate tolerance, down-regulation of LPS receptors on the surface of immune cells or over-production of anti-inflammatory mediators such as IL-10, TGF- $\beta$  and NO may also be in-

volved (Zingarelli et al. 1995; Fahmi et al. 1995; Dobrovolskaia and Vogel 2002). Indeed, NO had been proposed as a candidate mediator of malarial tolerance in endemic regions on the basis of studies suggesting a role in the mediation of endotoxin tolerance (Zingarelli et al. 1995) and preliminary observations in human studies (Clark et al. 1996; Anstey et al. 1999b). The subsequent demonstration that NO is dispensable to the development of endotoxin tolerance in NO synthase-2-knockout mice (Zingarelli et al. 2002) and recent contradictory data from human studies (Boutlis et al. 2004) casts doubt on these suggestions.

The recent demonstration that *P. falciparum* may initiate intracellular signalling through TLR2 and TLR4 (Krishnegowda et al. 2004) provides insight into the mechanisms that may underlie tolerance to malaria infection. Like *P. falciparum* GPIs, the GPI-mucin of *T. cruzi* appears to be recognised by both TLR2 and TLR4 (Campos et al. 2001; Ropert and Gazzinelli 2004; Oliveira et al. 2004); indeed, detailed studies have demonstrated that *T. cruzi* GPI-mucin and *E. coli* LPS use functionally similar pathways to induce TNF- $\alpha$  and IL-12 production in murine macrophages, with levels of both cytokines reduced in response to secondary stimuli (Ropert et al. 2001). This mirrors other models of cross-tolerance induced by differential induction of TLR2/TLR4 (Lehner et al. 2001; Beutler et al. 2001), consistent with these receptors sharing common intracellular pathways. The practical relevance of these studies to human malaria may have been hinted at as long as 50 years ago when it was shown that even a first malaria infection could induce cross-tolerance to endotoxin in experimentally infected humans (Heyman and Beeson 1949; Rubenstein et al. 1965). It is unclear, however, whether possible LPS contamination of the parasite preparations used in these studies may have confounded this effect. Considering the accumulated evidence, it would appear the most likely candidate model for malarial tolerance is one that parallels bacterial endotoxin tolerance.

## 4.2

### Anti-GPI Antibodies in Human Malaria

The recent purification of GPI in sufficient quantities for analysis has enabled the study of anti-GPI responses in human malaria. The strong theme to emerge from all studies conducted in malaria-endemic regions to date is that both the population prevalence and level of antibody responses increases with age (Naik et al. 2000a; de Souza et al. 2002; Boutlis et al. 2002; Hudson Keenihan et al. 2003; Suguitan et al. 2004). That this was true in a population exposed to perennially intense malaria transmission from birth (Boutlis et al. 2002), as well as Javanese transmigrants experiencing their first malaria

attacks in hyper-endemic Indonesian Papua (Hudson Keenihan et al. 2003), would suggest that immunological changes related to ageing are at least as important as those relating to cumulative exposure in determining antibody production. Antibodies to *P. falciparum* GPIs are infrequent in children less than 2 years of age (Naik et al. 2000a), possibly due to the inability of the immune system of small children to respond to carbohydrate antigens, but the age-relationship of anti-GPI antibody production thereafter closely mirrors that of a number of other blood-stage malaria peptide antigens (Al Yaman et al. 1994, 1995a, 1995b; Johnson et al. 2000). Field studies have shown that the anti-GPI antibody response is boostable by recent infection (de Souza et al. 2002; Hudson Keenihan et al. 2003), predominantly IgG rather than IgM (Naik et al. 2000a; Boutlis et al. 2002), and highly skewed towards the IgG3 subclass, especially in children (Boutlis et al. 2003a). Anti-GPI antibody responses decay rapidly after elimination of parasites by chemotherapy, suggesting that ongoing antigenic stimulation is required to maintain antibody production; the very rapid decline in treated children compared to treated adults (Boutlis et al. 2002) probably reflects the preponderance of IgG3 in children's plasma (Boutlis et al. 2003a), as IgG3 has a shorter half-life in serum than other IgG subclasses.

The relationship between anti-GPI antibodies and clinical malaria has been evaluated in a number of studies. In a study of Kenyan children and their mothers, seropositivity for anti-GPI antibodies was associated with lower body temperature and higher haemoglobin levels after adjusting for age and parasitaemia (Naik et al. 2000a). However, it was unclear from the data presented whether the association with lower body temperatures directly translated to a lower risk of acute febrile illness. In a prospective study in Gambian children aged 3–8 years, antibody levels at the beginning of the transmission season were not significantly predictive of the subsequent risk of mild malaria after controlling for age (de Souza et al. 2002); nor was there any significant difference in anti-GPI response between hospital-admitted Gambian children with severe (mainly cerebral) malaria or mild malaria in an independent case-control study (de Souza et al. 2002). Interestingly, several children with severe malaria had exceedingly high titres of anti-GPI antibodies in this study, which may have been due to rapid boosting of anti-GPI titres by the current infection. A study of Javanese transmigrants appeared to show that children aged 6–12 years (but not adults) with a positive anti-GPI response following infection had reduced subsequent risk of symptomatic disease (Hudson Keenihan et al. 2003). However, the analysis may have been influenced by the use of multiple measurements from the same child and the lack of adjustment for age; a similar finding was initially noted in the Gambian children, but disappeared after adjusting for the confounding effect of age (de


Souza et al. 2002). A cross-sectional study from Cameroon of anti-GPI antibody responses in pregnant women at delivery showed no relationship with acute or chronic placental pathology, TNF- $\alpha$  levels or pregnancy outcomes (Suguitan et al. 2004). Again, boosting of anti-GPI antibody concentration by the current malaria infection may have obscured important differences in GPI levels earlier in pregnancy.

In summary, investigators have consistently shown that the prevalence, persistence and level of anti-GPI antibodies increase with age in malaria-exposed populations. To date, however, there is little evidence to show that the antibody responses measured correlate with protection against clinical malaria or disease severity. However, it should be borne in mind that none of these studies was primarily designed to evaluate the potential clinical roles of anti-GPI antibodies, and that future hypothesis-driven studies will likely provide more robust results. Crucially, more prospective studies are required in which measures of anti-GPI antibodies prior to infection can be tested for association with outcome of subsequent infection; notwithstanding the major logistical problems associated with prospective studies of severe malaria. The use of fully synthetic GPIs (Lu et al. 2004; Liu and Seeberger 2004; Seeberger et al. 2004) will help dispel any doubt that the responses measured are specific, and combining clinical studies with functional assays (such as toxin neutralisation) will provide the clearest outcomes.

#### 4.3

##### **Antigen Recognition and Processing of GPIs**

Although several life cycle stages of *Plasmodium* express GPIs, initiation of immune responses likely occurs during asexual schizogony, when the highest concentrations of free GPI are released (Fig. 2). Early studies, conducted in immunocompetent and T-cell-deficient mice, suggested that non-protein antigens derived from the boiled supernatants of in vitro *P. falciparum* cultures induced a predominantly IgM response (Bate et al. 1990; Playfair et al. 1991). Serum from the mice could be used to block toxin-induced TNF- $\alpha$  production in vitro and in vivo (Playfair et al. 1991); this response appeared rapidly after immunisation and did not appear to be enhanced by boosting (Bate et al. 1992a) or common adjuvants (Playfair et al. 1990). This is typical of T-cell-independent antibody responses (Baumgarth 2000), but is at odds with the typical antibody responses to *P. falciparum* GPIs described in humans, which are IgG dominated (Naik et al. 2000a; Boutlis et al. 2002), characterised by skewing toward IgG3 (Boutlis et al. 2003a), and rapidly boosted by reinfection. This contrasts with the IgG2- and IgG1-dominated responses that have been described toward carbohydrate antigens such as bacterial polysaccha-



**Fig. 2** Proposed cellular interactions in the generation of anti-GPI antibodies. Schizogony is accompanied by the release of merozoites with GPI-linked surface proteins and by free GPI. GPIs provide activation signals for antigen presenting cells (APC) and macrophages ( $M\phi$ ). Parasite material is internalised by APCs and after processing through the endosomal/lysosomal pathway, peptides are presented in association with MHC class II to T cells. Meanwhile B cells may recognise free GPI or GPI bound to merozoites and become activated through cross-linking of the B cell receptor and by helper cytokines released by T cells (arrows 1 and 2). B cell activation leads either to plasma cell differentiation and large scale production of anti-GPI antibody or to formation of GPI-specific memory B cells ( $B_M$ ). Alternatively, GPI-specific B cells may internalise GPI-containing parasite material and present processed MHC class II-linked peptides to T cells. GPIs may also trigger APCs to produce IL-12 and IL-23 which regulate the function of other classes of T cell. IL-23-activated memory T cells ( $Th1_M$ ) produce IFN- $\gamma$  which in turn acts on B cells [(arrow 3), contributing to affinity maturation and Ig class switching) or macrophages (inducing anti-parasitic effector activity)]. The role of CD1d in the presentation of GPI-linked peptide to NKT cells remains controversial; however, it is likely that NKT cells respond following activation by IL-12/23 released by GPI-activated APC

rides (reviewed by Ferrante et al. 1990) and may indicate that GPI-anchored proteins act as natural adjuvants in eliciting immunological memory to *P. falciparum* GPIs. The apparent absence of IgG2 and IgG4 and the high ratio of IgG3 to IgG1 subclasses that we have observed (Boutlis et al. 2003a) are re-

markedly similar to the pattern of responses previously described in Solomon Islanders (Rzepczyk et al. 1997) and Gambians (Taylor et al. 1998) to MSP-2, which is a GPI-linked protein.

Given the absence of peptide epitopes for conventional T cells, antibody responses to free GPIs are likely to be T-cell-independent during a primary malaria infection. During a secondary response, however, activated GPI-specific B-cells may internalise and process GPI-linked proteins, possibly in the form of membrane vesicles (Hoessli et al. 2003), and subsequently present peptides derived from these GPI-linked proteins to CD4<sup>+</sup> T cells in the context of major histocompatibility complex class II (MHC-II). This would allow provision of cognate T-cell help to GPI-specific B-cells, via a classical hapten-carrier interaction, leading to immunoglobulin class switching, somatic mutation and affinity maturation of the BCR and generation of long-lived plasma cells and memory B-cells. As cognate interactions are most likely to take place between GPI-specific B cells and T cells recognising peptide epitopes that are physically linked to GPI, it is probable that T-cell help for GPI-specific B cells is provided by T cells specific for GPI-linked proteins and thus that anti-GPI antibodies may share qualitative features with antibodies to, for example, merozoite surface proteins. It is possible, for example, that the predominantly IgG3 subclass response to GPIs is mediated by T cells specific for MSP-2, which is known to induce IgG3 (Rzepczyk et al. 1997; Taylor et al. 1998). In support of this hypothesis, in the absence of covalently linked proteins, GPIs from the protozoal parasite *T. cruzi* can induce a switch from IgM to IgG production in murine B cells only in the presence of the T-cell-derived cytokines IL-4 and IL-5 (Bento et al. 1996).

Little is known of the primary immune response to *P. falciparum* GPIs, although it is likely to involve interactions with pattern recognition molecules (such as TLRs) expressed by dendritic cells and/or macrophages in the spleen (Stevenson and Riley 2004). Various types of lipid and glycolipid molecules can also be presented to NK T cells by CD1 molecules, which are MHC-like molecules encoded by genes outside the MHC (Sieling et al. 1995). CD1 molecules are expressed on the surface of antigen-presenting cells, e.g. macrophages, dendritic cells and B-cells (Kronenberg et al. 2001). Human CD1b has been shown to bind and present the mycobacterial lipoglycans, lipoarabinomannan and PI mannosides, which have a similar basic lipid anchor to *P. falciparum* GPIs (Sieling et al. 1995). In the presence of lipoarabinomannan and CD1<sup>+</sup> antigen-presenting cells, CD1b-restricted T cells taken from the skin of a patient with leprosy have been shown to induce IgG1 and IgG3 subclass antibody production by B cells at the expense of IgG4 and IgE (Fujieda et al. 1998). Mouse CD1d (which is highly homologous to human CD1d) (Porcelli and Modlin 1999) binds GPI with high affinity via the PI



moiety (Joyce et al. 1998) and has been shown to strongly stimulate natural killer NK T cells in vitro after binding a variety of purified phospholipids (including PI) (Gumperz et al. 2000).

Whether or not CD1d molecules recognise malarial GPIs is controversial. It has been reported that CD1d-restricted presentation of GPI-anchored *P. falciparum* (sporozoite) surface proteins leads to NK T-cell stimulation and that presentation of *P. berghei* circumsporozoite antigen (thought to be GPI anchored) by CD1d elicits NK T-cell help in regulating IgG production (Schofield et al. 1999). However, two independent laboratories, in attempting to replicate these results using CD1d and MHC-II-deficient mice, have demonstrated that the IgG response to the circumsporozoite protein is solely MHC-II-dependent (Molano et al. 2000; Romero et al. 2001), in line with previous evidence (Romero et al. 1988). Genetic differences between the mice used in the three studies were thought not to explain the discrepant results (Romero et al. 2001). Similarly conflicting results have emerged regarding the role for CD1d-restricted NK T-cell-mediated regulation of antibody responses to *T. cruzi* GPIs (Procopio et al. 2002; Duthie et al. 2002), which share structural similarities with those of *P. falciparum* (Naik et al. 2000a). It may be that differences in the process of antigen presentation (exogenous versus endogenous) (Hansen et al. 2003a) or kinetics of the antibody responses (Hansen et al. 2003b) can explain these apparent contradictions. Most recently it has been demonstrated that CD1d-restricted NK T cells appear to influence the balance of IFN- $\gamma$ /IL-4 cytokine production, pathogenesis and fatality in the murine *P. berghei* (ANKA) model (Hansen et al. 2003a, 2003b), as well as regulating B-cell-mediated antibody responses, which to MSP-1 at least were shown to arise from both CD1d-dependent and MHC-II-dependent pathways (Hansen et al. 2003b).

## 5

### Potential for Therapeutic Inhibition of *P. falciparum* GPI Biosynthesis

GPIs and their anchored proteins appear to mediate critical events in malaria pathogenesis and immunity (Sects. 2 and 4), and their production appears crucial for the survival of *P. falciparum* (Naik et al. 2000b). Thus, therapeutic targeting of *P. falciparum* GPI biosynthesis has the potential to arrest disease by affecting parasite growth, development and virulence. Although the core structure of GPIs is conserved across eukaryotes, available evidence suggests that sufficient differences exist in the specificity and sequence of GPI synthesis reactions to enable species-specific pharmacological manipulation (reviewed by de Macedo et al. 2003). While an ideal inhibitor of *P.*



*falciparum* GPI synthesis would have little or no effect on mammalian GPI synthesis, absolute specificity may not be essential, given that normal levels of GPI synthesis are in some instances dispensable for mammalian cell survival (Ferguson 1999).

Proof in the concept of selective enzyme inhibition has been demonstrated for a fungal metabolite that inhibited mammalian, but not protozoal, GPIs (Sutterlin et al. 1997) and has been validated at different stages of GPI assembly in *T. brucei* and *Leishmania mexicana* (Smith et al. 1997, 1999, 2001, 2004; Ferguson 2000). These studies have provided the methodological basis to compare GPI synthesis between *P. falciparum* and man. Consequently, a synthetic glucosamine-*N*-acetyl-PI analogue has been shown to irreversibly inhibit the *P. falciparum* de-*N*-acetylase, and an isomer of glucosamine-*N*-PI appears to competitively inhibit either the inositol-transferase or first mannosyltransferase, with little apparent effect on the human orthologues (Smith et al. 2002). Others have shown that early steps in *P. falciparum* GPI assembly can be aborted by using glucosamine (Naik et al. 2003) or modified sugar residues like mannosamine (2-amino-2-deoxy-*D*-mannose), which inhibits parasite growth (Naik et al. 2000b). However, results have been inconsistent between studies and the precise mechanisms of activity remain unclear (Naik et al. 2000b; Santos de Macedo et al. 2001). Further potential exists for targeting other pathways intricately linked to early GPI biosynthesis, such as the supply of PI, activated sugars and lipid chains (Eisenhaber et al. 2003).

The apparent importance of the side-chain Man<sub>4</sub> of *P. falciparum* GPIs to cell signalling and its likely requirement for protein anchoring (Naik et al. 2000a) makes the process of its addition an attractive therapeutic target. This is particularly so given that the process of cellular activation is currently thought to be novel, as it does not appear to involve membrane insertion or endocytosis (Gowda 2002). The fatty acyl requirements for cellular activation are still somewhat unclear, although it appears that features common to *P. falciparum* but absent in mammalian GPIs are important for activity (Gowda 2002). Although it was recently shown that Man<sub>4</sub>-GPIs are much more common in humans than previously realised, it was also demonstrated that protein transfer to human GPIs occurs irrespective of the presence of Man<sub>4</sub> or Man<sub>3</sub>-GPI precursors (Taron et al. 2004). Prior addition of Man<sub>4</sub> is mandatory for GPI protein anchoring in *Saccharomyces cerevisiae* (Grimme et al. 2001) and is likely to be a requirement in *P. falciparum*, given that all GPI protein anchors discovered to date possess a fourth mannose (Naik et al. 2000a). Together, these findings suggest that differences in the specificities of human, yeast and *P. falciparum* transamidase complexes for Man<sub>3</sub>/Man<sub>4</sub> GPI precursors can be expected and potentially exploited, perhaps even in a tissue-specific manner (Taron et al. 2004). Further definition of the genes and proteins involved in

*P. falciparum* GPI synthesis, and how their substrate specificities differ from humans, will help to determine whether anti-GPI pharmacological therapy can indeed become a reality.

## 6

### Prospects for Anti-GPI Vaccination

If the primary goal of active malaria vaccination is to protect malaria-exposed children from severe disease, then inhibiting toxin-induced pathophysiological responses is a potentially useful strategy. Immunisation of mice with deacylated synthetic *P. falciparum* GPI glycan conjugated to keyhole limpet haemocyanin reduced the early mortality of *P. berghei* (ANKA) challenge from 100% to 25% (Schofield et al. 2002). The glycan GPI analogue induced IgG antibodies in immunised mice that bound to intact intra-erythrocytic trophozoites and schizonts but did not cross-react with uninfected erythrocytes (which express endogenous GPIs on their surface). Serum from immunised mice completely neutralised production of TNF- $\alpha$  by mouse macrophages in response to stimulation by crude *P. falciparum* schizont extracts, suggesting that GPI alone is both sufficient and necessary for the induction of this inflammatory response. However, the early protection noted was independent of any reduction in parasitaemia, and immunised rodents eventually succumbed to haemolytic anaemia accompanied by massive parasitaemia. Other investigators have thus urged caution with GPI vaccination studies, especially given that *P. falciparum* GPIs are implicated in cell-mediated host-defence responses in addition to pathogenesis (Clark et al. 2004).

Vaccination specifically targeted at GPIs in humans raises concerns that vaccinated individuals with malaria would feel less sick and thus present to hospital later and with extremely high levels of parasitaemia, with the attendant risks of severe anaemia and organ failure. Inhibition of GPI-mediated early pro-inflammatory cytokine responses that limit parasite replication may also favour rapid rises in parasitaemia in vaccinated individuals (Kwiatkowski 1995). These concerns may be offset if anti-toxic vaccine antigen(s) were to be combined with epitopes primarily directed at generating an anti-parasitic response that limited exponential expansion in parasitaemia. However, this would require at least partial anti-parasitic efficacy in 100% of subjects receiving a combination vaccine—a target that would be very difficult to achieve. Moreover, the anti-parasitic immune responses induced by such a vaccine combination would need to be of longer duration than that of the anti-GPI immune response—again a difficult target. Active vaccination against GPI antigens may also theoretically interfere with any protective effect of NO

against malarial disease severity (Anstey et al. 1996; Hobbs et al. 2002), given that *P. falciparum* GPIs have been shown to induce NO production in vitro (Tachado et al. 1996). Passive immunisation of individuals with severe malaria by administration of monoclonal or polyclonal anti-GPI antibodies is an alternative adjunctive therapeutic strategy that may avoid interfering with early immune responses, and be transient enough to avoid long-term problems. In support of this approach, polyclonal antibody preparations that recognise bacterial super-antigens have been reported to improve clinical outcomes in streptococcal toxic shock syndrome (Kaul et al. 1999), which shares several features of the Th1 cytokine-dominated inflammatory response to severe malaria (Norrby-Teglund et al. 1997).

Field studies highlight the challenges involved in generating a sustained anti-GPI antibody response in children less than 5 years of age, which is the highest priority for vaccination in malaria-endemic areas. Understanding whether the events involved in GPI antigen presentation and processing (Sect. 4.3) can be modified by adjuvants (including other malarial antigens) or immuno-modulators may help to improve vaccine immunogenicity in this age group. Finally, given the conservation in the core structure of GPIs across eukaryotes, it would be important for anti-GPI vaccination to avoid inducing auto-immune responses. The finding that spleen cells primed with parasite-derived or mammalian Thy-1 derived GPI later responded to both homologous and heterologous antigenic challenge (Schofield et al. 1999) highlights these concerns.

## 7

### Conclusion

At present, although data from model systems are encouraging, there is very little firm evidence to suggest that antibody-mediated immune responses to *P. falciparum* GPIs play a significant role in either mediating tolerance or reducing disease severity in human malaria. Concerns over the purity of GPI preparations derived from *P. falciparum*, in relation to the specific induction of both pathological and immune responses, can be effectively dispelled if results can be repeated using fully synthetic preparations. It is exciting to think that the availability of synthetic GPIs may enable detailed and direct examination of the human fever responses in much the same way as human volunteers have contributed to our understanding of the modes of action of bacterial lipopolysaccharides (van der Poll and van Deventer 1999). A theoretical, but real, concern that must be addressed prior to such human studies involves determining the likelihood of cross-reactive, and potentially auto-

immune, antibody responses. Should the pathological significance of GPIs be confirmed by further studies of pathophysiology and/or natural immunity, then strategies to address the potential for unchecked parasite replication in the face of vaccination must be considered. Such concerns are less relevant for the development of selective pharmacological inhibitors of *P. falciparum* GPI biosynthesis; although confirmation that GPIs are essential to ongoing parasite replication is a pre-requisite if this approach is to be successful.

## References

- Aidoo M, McElroy PD, Kolczak MS, Terlouw DJ, ter Kuile FO, Nahlen B, Lal AA, Udhayakumar V (2001) Tumor necrosis factor- $\alpha$  promoter variant 2 (TNF2) is associated with pre-term delivery, infant mortality, and malaria morbidity in western Kenya: Asembo Bay Cohort Project IX. *Genet Epidemiol* 21:201–211
- Akira S, Hemmi H (2003) Recognition of pathogen-associated molecular patterns by TLR family. *Immunol Lett* 85:85–95
- Al Yaman F, Genton B, Anders RF, Falk M, Triglia T, Lewis D, Hii J, Beck HP, Alpers MP (1994) Relationship between humoral response to *Plasmodium falciparum* merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea. *Am J Trop Med Hyg* 51:593–602
- Al Yaman F, Genton B, Falk M, Anders RF, Lewis D, Hii J, Beck HP, Alpers MP (1995a) Humoral response to *Plasmodium falciparum* ring-infected erythrocyte surface antigen in a highly endemic area of Papua New Guinea. *Am J Trop Med Hyg* 52:66–71
- Al Yaman F, Genton B, Kramer KJ, Taraika J, Chang SP, Hui GS, Alpers MP (1995b) Acquired antibody levels to *Plasmodium falciparum* merozoite surface antigen 1 in residents of a highly endemic area of Papua New Guinea. *Trans R Soc Trop Med Hyg* 89:555–559
- Anstey NM, Weinberg JB, Hassanali MY, Mwaikambo ED, Manyenga D, Misukonis MA, Arnelle DR, Hollis D, McDonald MI, Granger DL (1996) Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. *J Exp Med* 184:557–567
- Anstey N, Weinberg J, Granger D (1999a) Nitric oxide and malaria. In: Fang FC (ed) *Nitric oxide and infection*. Plenum Publishing Corp., New York, pp 311–341
- Anstey NM, Weinberg JB, Wang Z, Mwaikambo ED, Duffy PE, Granger DL (1999b) Effects of age and parasitemia on nitric oxide production/leukocyte nitric oxide synthase type 2 expression in asymptomatic, malaria-exposed children. *Am J Trop Med Hyg* 61:253–258
- Arese P, Schwarzer E (1997) Malarial Pigment (Haemozoin) - a Very Active Inert Substance. *Annals of Tropical Medicine & Parasitology* 91:501–516
- Artavanis-Tsakonas K, Tongren JE, Riley EM (2003) The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. *Clin Exp Immunol* 133:145–152
- Baird JK (1998) Age-dependent characteristics of protection v. susceptibility to *Plasmodium falciparum*. *Ann Trop Med Parasitol* 92:367–390

- Baird JK, Masbar S, Basri H, Tirtokusumo S, Subianto B, Hoffman SL (1998) Age-dependent susceptibility to severe disease with primary exposure to *Plasmodium falciparum*. *J Infect Dis* 178:592–595
- Basilio N, Tognazioli C, Picot S, Ravagnani F, Taramelli D (2003) Synergistic and antagonistic interactions between haemozoin and bacterial endotoxin on human and mouse macrophages. *Parassitologia* 45:135–140
- Bate CA, Kwiatkowski D (1994a) A monoclonal antibody that recognizes phosphatidylinositol inhibits induction of tumor necrosis factor alpha by different strains of *Plasmodium falciparum*. *Infect Immun* 62:5261–5266
- Bate CA, Kwiatkowski D (1994b) Inhibitory immunoglobulin M antibodies to tumor necrosis factor-inducing toxins in patients with malaria. *Infect Immun* 62:3086–3091
- Bate CA, Taverne J, Playfair JH (1988) Malarial parasites induce TNF production by macrophages. *Immunology* 64:227–231
- Bate CA, Taverne J, Dave A, Playfair JH (1990) Malaria exoantigens induce T-independent antibody that blocks their ability to induce TNF. *Immunology* 70:315–320
- Bate CA, Taverne J, Bootsma HJ, Mason RC, Skalko N, Gregoriadis G, Playfair JH (1992a) Antibodies against phosphatidylinositol and inositol monophosphate specifically inhibit tumour necrosis factor induction by malaria exoantigens. *Immunology* 76:35–41
- Bate CA, Taverne J, Roman E, Moreno C, Playfair JH (1992b) Tumour necrosis factor induction by malaria exoantigens depends upon phospholipid. *Immunology* 75:129–135
- Baumgarth N (2000) A two-phase model of B-cell activation. *Immunol Rev* 176:171–180
- Bayley JP, Ottenhoff TH, Verweij CL (2004) Is there a future for TNF promoter polymorphisms? *Genes Immun* 5:315–329
- Bento CA, Melo MB, Previato JO, Mendonca-Previato L, Pecanha LM (1996) Glycoinositolphospholipids purified from *Trypanosoma cruzi* stimulate Ig production in vitro. *J Immunol* 157:4996–5001
- Berhe S, Schofield L, Schwarz RT, Gerold P (1999) Conservation of structure among glycosylphosphatidylinositol toxins from different geographic isolates of *Plasmodium falciparum*. *Mol Biochem Parasitol* 103:273–278
- Beutler E, Gelbart T, West C (2001) Synergy between TLR2 and TLR4: a safety mechanism. *Blood Cells Mol Dis* 27:728–730
- Biswas S, Karmakar MG, Sharma YD (2001) Antibodies detected against *Plasmodium falciparum* haemozoin with inhibitory properties to cytokine production. *FEMS Microbiol Lett* 194:175–179
- Boisier P, Jambou R, Raharimalala L, Roux J (2002) Relationship between parasite density and fever risk in a community exposed to a low level of malaria transmission in Madagascar highlands. *Am J Trop Med Hyg* 67:137–140
- Boutlis CS, Gowda DC, Naik RS, Maguire GP, Mgone CS, Bockarie MJ, Lagog M, Ibam E, Lorry K, Anstey NM (2002) Antibodies to *Plasmodium falciparum* glycosylphosphatidylinositols: inverse association with tolerance of parasitemia in Papua New Guinean children and adults. *Infect Immun* 70:5052–5057

- Boutlis CS, Fagan PK, Gowda DC, Lagog M, Mgone CS, Bockarie MJ, Anstey NM (2003a) Immunoglobulin G responses to *Plasmodium falciparum* glycosylphosphatidylinositols are short-lived and predominantly of the IgG3 subclass. *J Infect Dis* 187:862–865
- Boutlis CS, Tjitra E, Maniboeu H, Misukonis MA, Saunders JR, Suprianto S, Weinberg JB, Anstey NM (2003b) Nitric oxide production and mononuclear cell nitric oxide synthase activity in malaria-tolerant Papuan adults. *Infect Immun* 71:3682–3689
- Boutlis CS, Weinberg JB, Baker J, Bockarie MJ, Mgone CS, Cheng Q, Anstey NM (2004) Nitric oxide production and nitric oxide synthase activity in malaria-exposed Papua New Guinean children and adults show longitudinal stability and no association with parasitemia. *Infect Immun* 72:6932–6938
- Bruce MC, Donnelly CA, Alpers MP, Galinski MR, Barnwell JW, Walliker D, Day KP (2000) Cross-species interactions between malaria parasites in humans. *Science* 287:845–848
- Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT (2004) Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of *Plasmodium* lacking the GPI-anchoring motif. *Vaccine* 22:3575–3584
- Calissano C, Modiano D, Sirima BS, Konate A, Sanou I, Sawadogo A, Perlmann H, Troye-Blomberg M, Perlmann P (2003) IgE antibodies to *Plasmodium falciparum* and severity of malaria in children of one ethnic group living in Burkina Faso. *Am J Trop Med Hyg* 69:31–35
- Campos MA, Almeida IC, Takeuchi O, Akira S, Valente EP, Procopio DO, Travassos LR, Smith JA, Golenbock DT, Gazzinelli RT (2001) Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. *J Immunol* 167:416–423
- Chatterjee S, Mayor S (2001) The GPI-anchor and protein sorting. *Cell Mol Life Sci* 58:1969–1987
- Chen R, Walter EI, Parker G, Lapurga JP, Millan JL, Ikehara Y, Udenfriend S, Medof ME (1998) Mammalian glycosylphosphatidylinositol anchor transfer to proteins and posttransfer deacylation. *Proc Natl Acad Sci U S A* 95:9512–9517
- Clark IA (1978) Does endotoxin cause both the disease and parasite death in acute malaria and babesiosis? *Lancet* 2:75–77
- Clark IA, Cowden WB (2003) The pathophysiology of falciparum malaria. *Pharmacol Ther* 99:221–260
- Clark IA, Virelizier JL, Carswell EA, Wood PR (1981) Possible importance of macrophage-derived mediators in acute malaria. *Infect Immun* 32:1058–1066
- Clark IA, Cowden WB, Butcher GA, Hunt NH (1987) Possible roles of tumor necrosis factor in the pathology of malaria. *Am J Pathol* 129:192–199
- Clark IA, Gray KM, Rockett EJ, Cowden WB, Rockett KA, Ferrante A, Aggarwal BB (1992) Increased lymphotoxin in human malarial serum, and the ability of this cytokine to increase plasma interleukin-6 and cause hypoglycaemia in mice: implications for malarial pathology. *Trans R Soc Trop Med Hyg* 86:602–607
- Clark IA, al Yaman FM, Cowden WB, Rockett KA (1996) Does malarial tolerance, through nitric oxide, explain the low incidence of autoimmune disease in tropical Africa? *Lancet* 348:1492–1494

- Clark IA, al Yaman FM, Jacobson LS (1997) The biological basis of malarial disease. *Int J Parasitol* 27:1237–1249
- Clark IA, Awburn MM, Harper CG, Liomba NG, Molyneux ME (2003a) Induction of HO-1 in tissue macrophages and monocytes in fatal falciparum malaria and sepsis. *Malar J* 2:41–
- Clark IA, Awburn MM, Whitten RO, Harper CG, Liomba NG, Molyneux ME, Taylor TE (2003b) Tissue distribution of migration inhibitory factor and inducible nitric oxide synthase in falciparum malaria and sepsis in African children. *Malar J* 2:6–
- Clark IA, Alleva LM, Mills AC, Cowden WB (2004) Pathogenesis of malaria and clinically similar conditions. *Clin Microbiol Rev* 17:509–539
- Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, Yamamoto M, Takeuchi O, Itagaki S, Kumar N, Horii T, Akira S (2005) Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. *J Exp Med* 201:19–25
- de Macedo CS, Shams-Eldin H, Smith TK, Schwarz RT, Azzouz N (2003) Inhibitors of glycosyl-phosphatidylinositol anchor biosynthesis. *Biochimie* 85:465–472
- de Souza JB, Todd J, Krishegowda G, Gowda DC, Kwiatkowski D, Riley EM (2002) Prevalence and boosting of antibodies to *Plasmodium falciparum* glycosylphosphatidylinositols and evaluation of their association with protection from mild and severe clinical malaria. *Infect Immun* 70:5045–5051
- Delorenzi M, Sexton A, Shams-Eldin H, Schwarz RT, Speed T, Schofield L (2002) Genes for glycosylphosphatidylinositol toxin biosynthesis in *Plasmodium falciparum*. *Infect Immun* 70:4510–4522
- Dobrovolskaia MA, Vogel SN (2002) Toll receptors, CD14, and macrophage activation and deactivation by LPS. *Microbes Infect* 4:903–914
- Dodoo D, Omer FM, Todd J, Akanmori BD, Koram KA, Riley EM (2002) Absolute Levels and Ratios of Proinflammatory and Anti-inflammatory Cytokine Production In Vitro Predict Clinical Immunity to *Plasmodium falciparum* Malaria. *J Infect Dis* 185:971–979
- Duthie MS, Wleklinski-Lee M, Smith S, Nakayama T, Taniguchi M, Kahn SJ (2002) During *Trypanosoma cruzi* infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycosphosphoinositol- modified surface protein. *Infect Immun* 70:36–48
- Eisenhaber B, Maurer-Stroh S, Novatchkova M, Schneider G, Eisenhaber F (2003) Enzymes and auxiliary factors for GPI lipid anchor biosynthesis and post-translational transfer to proteins. *Bioessays* 25:367–385
- Elased KM, Gumaa KA, de Souza JB, Playfair JH, Rademacher TW (2004) Improvement of glucose homeostasis in obese diabetic db/db mice given *Plasmodium yoelii* glycosylphosphatidylinositols. *Metabolism* 53:1048–1053
- English M, Waruiru C, Amukoye E, Murphy S, Crawley J, Mwangi I, Peshu N, Marsh K (1996) Deep breathing in children with severe malaria: indicator of metabolic acidosis and poor outcome. *Am J Trop Med Hyg* 55:521–524
- Engwerda CR, Mynott TL, Sawhney S, de Souza JB, Bickle QD, Kaye PM (2002) Locally up-regulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria. *J Exp Med* 195:1371–1377
- Fahmi H, Charon D, Mondange M, Chaby R (1995) Endotoxin-induced desensitization of mouse macrophages is mediated in part by nitric oxide production. *Infect Immun* 63:1863–1869



- Fanning SL, Czesny B, Sedegah M, Carucci DJ, van Gemert GJ, Eling W, Williamson KC (2003) A glycosylphosphatidylinositol anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding *Plasmodium falciparum* sexual-stage antigen, Pfs230. *Vaccine* 21:3228–3235
- Farnert A, Snounou G, Rooth I, Bjorkman A (1997) Daily dynamics of *Plasmodium falciparum* subpopulations in asymptomatic children in a holoendemic area. *Am J Trop Med Hyg* 56:538–47
- Ferguson MA (1999) The structure, biosynthesis and functions of glycosylphosphatidylinositol anchors, and the contributions of trypanosome research. *J Cell Sci* 112 ( Pt 17):2799–2809
- Ferguson MA (2000) Glycosylphosphatidylinositol biosynthesis validated as a drug target for African sleeping sickness. *Proc Natl Acad Sci U S A* 97:10673–10675
- Ferlito M, Squadrito F, Halushka PV, Cook JA (2001) Signal transduction events in Chinese hamster ovary cells expressing human CD14; effect of endotoxin desensitization. *Shock* 15:291–296
- Ferrante A, Beard LJ, Feldman RG (1990) IgG subclass distribution of antibodies to bacterial and viral antigens. *Pediatr Infect Dis J* 9:S16–S24
- Fujieda S, Sieling PA, Modlin RL, Saxon A (1998) CD1-restricted T-cells influence IgG subclass and IgE production. *J Allergy Clin Immunol* 101:545–551
- Gatton ML, Cheng Q (2002) Evaluation of the pyrogenic threshold for *Plasmodium falciparum* malaria in naive individuals. *Am J Trop Med Hyg* 66:467–473
- Gerold P, Dieckmann-Schuppert A, Schwarz RT (1994) Glycosylphosphatidylinositols synthesized by asexual erythrocytic stages of the malarial parasite, *Plasmodium falciparum*. Candidates for plasmodial glycosylphosphatidylinositol membrane anchor precursors and pathogenicity factors. *J Biol Chem* 269:2597–2606
- Gerold P, Vivas L, Ogun SA, Azzouz N, Brown KN, Holder AA, Schwarz RT (1997) Glycosylphosphatidylinositols of *Plasmodium chabaudi chabaudi*: a basis for the study of malarial glycolipid toxins in a rodent model. *Biochem J* 328 (Pt 3):905–911
- Golgi C (1886) Sull'infezione malarica. *Archivio Per Le Scienze Mediche* 10:109–135
- Gowda DC (2002) Structure and activity of glycosylphosphatidylinositol anchors of *Plasmodium falciparum*. *Microbes Infect* 4:983–990
- Grau GE, Taylor TE, Molyneux ME, Wirima JJ, Vassalli P, Hommel M, Lambert PH (1989) Tumor necrosis factor and disease severity in children with *falciparum* malaria. *N Engl J Med* 320:1586–1591
- Grimme SJ, Westfall BA, Wiedman JM, Taron CH, Orlean P (2001) The essential Smp3 protein is required for addition of the side-branching fourth mannose during assembly of yeast glycosylphosphatidylinositols. *J Biol Chem* 276:27731–27739
- Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T, Koezuka Y, Porcelli SA, Cardell S, Brenner MB, Behar SM (2000) Murine CD1d-restricted T cell recognition of cellular lipids. *Immunity* 12:211–221
- Hansen DS, Siomos MA, Buckingham L, Scalzo AA, Schofield L (2003a) Regulation of murine cerebral malaria pathogenesis by CD1d-restricted NKT cells and the natural killer complex. *Immunity* 18:391–402
- Hansen DS, Siomos MA, Koning-Ward T, Buckingham L, Crabb BS, Schofield L (2003b) CD1d-restricted NKT cells contribute to malarial splenomegaly and enhance parasite-specific antibody responses. *Eur J Immunol* 33:2588–2598



- Heyman A, Beeson PB (1949) Influence of various disease states upon the febrile response to intravenous injection of typhoid bacterial pyrogen: with particular reference to malaria and cirrhosis of the liver. *J Lab Clin Med* 34:1400–1403
- Hisaeda H, Maekawa Y, Iwakawa D, Okada H, Himeno K, Kishihara K, Tsukumo S, Yasutomo K (2004) Escape of malaria parasites from host immunity requires CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cells. *Nat Med* 10:29–30
- Hobbs MR, Udhayakumar V, Levesque MC, Booth J, Roberts JM, Tkachuk AN, Pole A, Coon H, Kariuki S, Nahlen BL, Mwaikambo ED, Lal AL, Granger DL, Anstey NM, Weinberg JB (2002) A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. *Lancet* 360:1468–1475
- Hoessli DC, Poincelet M, Gupta R, Ilangumaran S, Nasir uD (2003) Plasmodium falciparum merozoite surface protein 1. *Eur J Biochem* 270:366–375
- Hudson Keenihan SN, Ratiwayanto S, Soebianto S, Krisin, Marwoto H, Krishnegowda G, Gowda DC, Bangs MJ, Fryauff DJ, Richie TL, Kumar S, Baird JK (2003) Age-dependent impairment of IgG responses to glycosylphosphatidylinositol with equal exposure to Plasmodium falciparum among Javanese migrants to Papua, Indonesia. *Am J Trop Med Hyg* 69:36–41
- Hunt NH, Grau GE (2003) Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. *Trends Immunol* 24:491–499
- Iuvone T, D'Acquisto F, Carnuccio R, Di Rosa M (1996) Nitric oxide inhibits LPS-induced tumor necrosis factor synthesis in vitro and in vivo. *Life Sci* 59:L207–L211
- Jaramillo M, Gowda DC, Radzioch D, Olivier M (2003) Hemozoin increases IFN-gamma-inducible macrophage nitric oxide generation through extracellular signal-regulated kinase- and NF-kappa B-dependent pathways. *J Immunol* 171:4243–4253
- Jaramillo M, Plante I, Ouellet N, Vandal K, Tessier PA, Olivier M (2004) Hemozoin-inducible proinflammatory events in vivo: potential role in malaria infection. *J Immunol* 172:3101–3110
- Jaramillo M, Godbout M, Olivier M (2005) Hemozoin induces macrophage chemokine expression through oxidative stress-dependent and -independent mechanisms. *J Immunol* 174:475–484
- Johnson A, Leke R, Harun L, Ginsberg C, Ngogang J, Stowers A, Saul A, Quakyi IA (2000) Interaction of HLA and age on levels of antibody to Plasmodium falciparum rhoptry-associated proteins 1 and 2. *Infect Immun* 68:2231–2236
- Joyce S, Woods AS, Yewdell JW, Bennink JR, De S, Boesteanu A, Balk SP, Cotter RJ, Brutkiewicz RR (1998) Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. *Science* 279:1541–1544
- Kastenbauer S, Ziegler-Heitbrock HW (1999) NF-kappaB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression. *Infect Immun* 67:1553–1559
- Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, Talbot J, Low DE (1999) Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. The Canadian Streptococcal Study Group. *Clin Infect Dis* 28:800–807

- Keller CC, Kremsner PG, Hittner JB, Misukonis MA, Weinberg JB, Perkins DJ (2004) Elevated nitric oxide production in children with malarial anemia: hemozoin-induced nitric oxide synthase type 2 transcripts and nitric oxide in blood mononuclear cells. *Infect Immun* 72:4868–4873
- Kern P, Hemmer CJ, Van Damme J, Gruss HJ, Dietrich M (1989) Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated *Plasmodium falciparum* malaria. *Am J Med* 87:139–143
- Kimmel J, Ogun SA, de Macedo CS, Gerold P, Vivas L, Holder AA, Schwarz RT, Azzouz N (2003) Glycosylphosphatidyl-inositols in murine malaria: *Plasmodium yoelii yoelii*. *Biochimie* 85:473–481
- Kinoshita T, Inoue N (2000) Dissecting and manipulating the pathway for glycosylphosphatidylinositol-anchor biosynthesis. *Curr Opin Chem Biol* 4:632–638
- Krishnegowda G, Hajjar AM, Zhu J, Douglass EJ, Uematsu S, Akira S, Woods AS, Gowda DC (2004) Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols (GPIs) of *Plasmodium falciparum*: Cell signaling receptors, GPI structural requirement, and regulation of GPI activity. *J Biol Chem* Dec 28: Epub ahead of print
- Kronenberg M, Naidenko O, Koning F (2001) Right on target: novel approaches for the direct visualization of CD1-specific T cell responses. *Proc Natl Acad Sci U S A* 98:2950–2952
- Kwiatkowski D (1995) Malarial toxins and the regulation of parasite density. *Parasitology Today* 11:206–212
- Kwiatkowski D, Cannon JG, Manogue KR, Cerami A, Dinarello CA, Greenwood BM (1989) Tumour necrosis factor production in *Falciparum* malaria and its association with schizont rupture. *Clin Exp Immunol* 77:361–366
- Kwiatkowski D, Molyneux ME, Stephens S, Curtis N, Klein N, Pointaire P, Smit M, Allan R, Brewster DR, Grau GE (1993) Anti-TNF therapy inhibits fever in cerebral malaria. *Q J Med* 86:91–98
- Latz E, Visintin A, Lien E, Fitzgerald K, Monks BG, Kurt-Jones E, Golenbock DT, Espevik T (2002) LPS rapidly traffics to and from the Golgi apparatus with the TLR4/MD-2/CD14 complex in a process that is distinct from the initiation of signal transduction. *J Biol Chem* 277:47834–47843
- Le Hesran JY, Akiana J, Ndiaye eH, Dia M, Senghor P, Konate L (2004) Severe malaria attack is associated with high prevalence of *Ascaris lumbricoides* infection among children in rural Senegal. *Trans R Soc Trop Med Hyg* 98:397–399
- Le Hesran JY (2005) Reply to comment on: Severe malaria attack is associated with high prevalence of *Ascaris lumbricoides* infection among children in rural Senegal. *Trans R Soc Trop Med Hyg* 99:164–165
- Lehner MD, Morath S, Michelsen KS, Schumann RR, Hartung T (2001) Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. *J Immunol* 166:5161–5167
- Li C, Sanni LA, Omer F, Riley E, Langhorne J (2003) Pathology of *Plasmodium chabaudi* *chabaudi* infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor alpha and exacerbated by anti-transforming growth factor beta antibodies. *Infect Immun* 71:4850–4856

- Liu X, Seeberger PH (2004) A Suzuki-Miyaura coupling mediated deprotection as key to the synthesis of a fully lipidated malarial GPI disaccharide. *Chem Commun (Camb)* 1708–1709
- Looareesuwan S, Sjostrom L, Krudsood S, Wilairatana P, Porter RS, Hills F, Warrell DA (1999) Polyclonal anti-tumor necrosis factor- $\alpha$  Fab used as an ancillary treatment for severe malaria. *Am J Trop Med Hyg* 61:26–33
- Lu J, Jayaprakash KN, Schlueter U, Fraser-Reid B (2004) Synthesis of a malaria candidate glycosylphosphatidylinositol (GPI) structure: a strategy for fully inositol acylated and phosphorylated GPIs. *J Am Chem Soc* 126:7540–7547
- Maeno Y, Perlmann P, Perlmann H, Kusuhara Y, Taniguchi K, Nakabayashi T, Win K, Looareesuwan S, Aikawa M (2000) IgE deposition in brain microvessels and on parasitized erythrocytes from cerebral malaria patients. *Am J Trop Med Hyg* 63:128–132
- Maitland K, Marsh K (2004) Pathophysiology of severe malaria in children. *Acta Trop* 90:131–140
- Marsh K, Snow RW (1997) Host-parasite interaction and morbidity in malaria endemic areas. *Philos Trans R Soc Lond B Biol Sci* 352:1385–94
- Martinez AP, Margos G, Barker G, Sinden RE (2000) The roles of the glycosylphosphatidylinositol anchor on the production and immunogenicity of recombinant ookinete surface antigen Pbs21 of *Plasmodium berghei* when prepared in a baculovirus expression system. *Parasite Immunol* 22:493–500
- McGregor IA, Gilles HM, Walters JH, Davies AH, Pearson FA (1956) Effects of heavy and repeated malarial infections on Gambian infants and children: effects of erythrocytic parasitization. *Br Med J* 4994:686–692
- McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D (1994) Variation in the TNF- $\alpha$  promoter region associated with susceptibility to cerebral malaria. *Nature* 371:508–510
- Menendez C, Fleming AF, Alonso PL (2000) Malaria-related anaemia. *Parasitol Today* 16:469–476
- Miller MJ (1958) Observations of the natural history of malaria in the semi-resistant west African. *Trans R Soc Trop Med Hyg* 52:152–168
- Missinou MA, Lell B, Kremsner PG (2003) Uncommon asymptomatic *Plasmodium falciparum* infections in Gabonese children. *Clin Infect Dis* 36:1198–1202
- Molano A, Park SH, Chiu YH, Nossair S, Bendelac A, Tsuji M (2000) Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPIs in NK T cell activation and antimalarial responses. *J Immunol* 164:5005–5009
- Molineaux L, Trauble M, Collins WE, Jeffery GM, Dietz K (2002) Malaria therapy reinoculation data suggest individual variation of an innate immune response and independent acquisition of antiparasitic and antitoxic immunities. *Trans R Soc Trop Med Hyg* 96:205–209
- Moran P, Caras IW (1994) Requirements for glycosylphosphatidylinositol attachment are similar but not identical in mammalian cells and parasitic protozoa. *J Cell Biol* 125:333–343

- Mordmuller B, Turrini F, Long H, Kremsner PG, Arese P (1998) Neutrophils and monocytes from subjects with the Mediterranean G6PD variant: effect of *Plasmodium falciparum* hemozoin on G6PD activity, oxidative burst and cytokine production. *Eur Cytokine Netw* 9:239–245
- Muniz-Junqueira MI, dos Santos-Neto LL, Tosta CE (2001) Influence of tumor necrosis factor- $\alpha$  on the ability of monocytes and lymphocytes to destroy intraerythrocytic *Plasmodium falciparum* in vitro. *Cell Immunol* 208:73–79
- Nacher M (2002) Worms and malaria: noisy nuisances and silent benefits. *Parasite Immunol* 24:391–393
- Nacher M (2005) Comment on: Severe malaria attack is associated with high prevalence of *Ascaris lumbricoides* infection among children in rural Senegal. *Trans R Soc Trop Med Hyg* 99:161–163
- Naik RS, Branch OH, Woods AS, Vijaykumar M, Perkins DJ, Nahlen BL, Lal AA, Cotter RJ, Costello CE, Ockenhouse CF, Davidson EA, Gowda DC (2000a) Glycosylphosphatidylinositol anchors of *Plasmodium falciparum*: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. *J Exp Med* 192:1563–1576
- Naik RS, Davidson EA, Gowda DC (2000b) Developmental stage-specific biosynthesis of glycosylphosphatidylinositol anchors in intraerythrocytic *Plasmodium falciparum* and its inhibition in a novel manner by mannosamine. *J Biol Chem* 275:24506–24511
- Naik RS, Krishnegowda G, Gowda CD (2003) Glucosamine inhibits inositol acylation of the glycosylphosphatidylinositol anchors in intraerythrocytic plasmodium falciparum. *J Biol Chem* 278:2036–2042
- Njama-Meya D, Kanya MR, Dorsey G (2004) Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children. *Trop Med Int Health* 9:862–868
- Norrby-Teglund A, Lustig R, Kotb M (1997) Differential induction of Th1 versus Th2 cytokines by group A streptococcal toxic shock syndrome isolates. *Infect Immun* 65:5209–5215
- Ockenhouse CF, Tegoshi T, Maeno Y, Benjamin C, Ho M, Kan KE, Thway Y, Win K, Aikawa M, Lobb RR (1992) Human vascular endothelial cell adhesion receptors for *Plasmodium falciparum*-infected erythrocytes: roles for endothelial leukocyte adhesion molecule 1 and vascular cell adhesion molecule 1. *J Exp Med* 176:1183–1189
- Oliveira AC, Peixoto JR, de Arruda LB, Campos MA, Gazzinelli RT, Golenbock DT, Akira S, Previato JO, Mendonca-Previato L, Nobrega A, Bellio M (2004) Expression of functional TLR4 confers proinflammatory responsiveness to *Trypanosoma cruzi* glycoinositolphospholipids and higher resistance to infection with *T. cruzi*. *J Immunol* 173:5688–5696
- Omer FM, Riley EM (1998) Transforming growth factor beta production is inversely correlated with severity of murine malaria infection. *J Exp Med* 188:39–48
- Omer FM, Kurtzhals JA, Riley EM (2000) Maintaining the immunological balance in parasitic infections: a role for TGF- $\beta$ ? *Parasitol Today* 16:18–23
- Omer FM, de Souza JB, Riley EM (2003) Differential induction of TGF- $\beta$  regulates proinflammatory cytokine production and determines the outcome of lethal and nonlethal *Plasmodium yoelii* infections. *J Immunol* 171:5430–5436

- Perkins DJ, Kremsner PG, Weinberg JB (2001) Inverse relationship of plasma prostaglandin E2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with *Plasmodium falciparum* malaria. *J Infect Dis* 183:113–118
- Perkins DJ, Moore JM, Otieno J, Shi YP, Nahlen BL, Udhayakumar V, Lal AA (2003) In vivo acquisition of hemozoin by placental blood mononuclear cells suppresses PGE2, TNF-alpha, and IL-10. *Biochem Biophys Res Commun* 311:839–846
- Perlmann P, Perlmann H, Flyg BW, Hagstedt M, Elghazali G, Worku S, Fernandez V, Rutta AS, Troye-Blomberg M (1997) Immunoglobulin E, a pathogenic factor in *Plasmodium falciparum* malaria. *Infect Immun* 65:116–121
- Pichyangkul S, Saengkrai P, Webster HK (1994) *Plasmodium falciparum* pigment induces monocytes to release high levels of tumor necrosis factor-alpha and interleukin-1 beta. *Am J Trop Med Hyg* 51:430–435
- Pichyangkul S, Yongvanitchit K, Kum-arb U, Hemmi H, Akira S, Krieg AM, Heppner DG, Stewart VA, Hasegawa H, Looareesuwan S, Shanks GD, Miller RS (2004) Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. *J Immunol* 172:4926–4933
- Playfair JH, Taverne J, Bate CA, de Souza JB (1990) The malaria vaccine: anti-parasite or anti-disease? *Immunol Today* 11:25–27
- Playfair JH, Taverne J, Bate CA (1991) Don't kill the parasite: control the disease. *Acta Leiden* 60:157–165
- Porcelli SA, Modlin RL (1999) The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. *Annu Rev Immunol* 17:297–329
- Prada J, Malinowski J, Muller S, Bienzle U, Kremsner PG (1995) Hemozoin differentially modulates the production of interleukin 6 and tumor necrosis factor in murine malaria. *Eur Cytokine Netw* 6:109–112
- Procopio DO, Almeida IC, Torrecilhas AC, Cardoso JE, Teyton L, Travassos LR, Bendelac A, Gazzinelli RT (2002) Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from *Trypanosoma cruzi* bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway. *J Immunol* 169:3926–3933
- Prybylski D, Khaliq A, Fox E, Sarwari AR, Strickland GT (1999) Parasite density and malaria morbidity in the Pakistani Punjab. *Am J Trop Med Hyg* 61:791–801
- Rae C, McQuillan JA, Parekh SB, Bubb WA, Weiser S, Balcar VJ, Hansen AM, Ball HJ, Hunt NH (2004) Brain gene expression, metabolism, and bioenergetics: interrelationships in murine models of cerebral and noncerebral malaria. *FASEB J* 18:499–510
- Riley EM (1999) Is T-cell priming required for initiation of pathology in malaria infections? *Immunol Today* 20:228–233
- Rogier C, Commenges D, Trape JF (1996) Evidence for an age-dependent pyrogenic threshold of *Plasmodium falciparum* parasitemia in highly endemic populations. *Am J Trop Med Hyg* 54:613–619
- Romero PJ, Tam JP, Schlesinger D, Clavijo P, Gibson H, Barr PJ, Nussenzweig RS, Nussenzweig V, Zavala F (1988) Multiple T helper cell epitopes of the circumsporozoite protein of *Plasmodium berghei*. *Eur J Immunol* 18:1951–1957

- Romero JF, Eberl G, MacDonald HR, Corradin G (2001) CD1d-restricted NK T cells are dispensable for specific antibody responses and protective immunity against liver stage malaria infection in mice. *Parasite Immunol* 23:267–269
- Robert C, Gazzinelli RT (2000) Signaling of immune system cells by glycosylphosphatidylinositol (GPI) anchor and related structures derived from parasitic protozoa. *Curr Opin Microbiol* 3:395–403
- Robert C, Gazzinelli RT (2004) Regulatory role of Toll-like receptor 2 during infection with *Trypanosoma cruzi*. *J Endotoxin Res* 10:425–430
- Robert C, Almeida IC, Closel M, Travassos LR, Ferguson MA, Cohen P, Gazzinelli RT (2001) Requirement of mitogen-activated protein kinases and I kappa B phosphorylation for induction of proinflammatory cytokines synthesis by macrophages indicates functional similarity of receptors triggered by glycosylphosphatidylinositol anchors from parasitic protozoa and bacterial lipopolysaccharide. *J Immunol* 166:3423–3431
- Rowe JA, Scragg IG, Kwiatkowski D, Ferguson DJ, Carucci DJ, Newbold CI (1998) Implications of mycoplasma contamination in *Plasmodium falciparum* cultures and methods for its detection and eradication. *Mol Biochem Parasitol* 92:177–180
- Rubenstein M, Mulholland J, Jeffery G, Wolff S (1965) Malaria induced endotoxin tolerance. *Proc Soc Exp Biol Med* 118:283–287
- Rzepczyk CM, Hale K, Woodroffe N, Bobogare A, Csurhes P, Ishii A, Ferrante A (1997) Humoral immune responses of Solomon Islanders to the merozoite surface antigen 2 of *Plasmodium falciparum* show pronounced skewing towards antibodies of the immunoglobulin G3 subclass. *Infect Immun* 65:1098–1100
- Sanchez-Cantu L, Rode HN, Christou NV (1989) Endotoxin tolerance is associated with reduced secretion of tumor necrosis factor. *Arch Surg* 124:1432–1435
- Santos de Macedo C, Gerold P, Jung N, Azzouz N, Kimmel J, Schwarz RT (2001) Inhibition of glycosyl-phosphatidylinositol biosynthesis in *Plasmodium falciparum* by C-2 substituted mannose analogues. *Eur J Biochem* 268:6221–6228
- Scheibhofer S, Chen D, Weiss R, Khan F, Mostbock S, Fegeding K, Leitner WW, Thalhamer J, Lyon JA (2001) Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specific Th2 type immune responses and improves protection against malaria infection. *Eur J Immunol* 31:692–698
- Schofield L, Hackett F (1993) Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites. *J Exp Med* 177:145–153
- Schofield L, Vivas L, Hackett F, Gerold P, Schwarz RT, Tachado S (1993) Neutralizing monoclonal antibodies to glycosylphosphatidylinositol, the dominant TNF-alpha-inducing toxin of *Plasmodium falciparum*: prospects for the immunotherapy of severe malaria. *Ann Trop Med Parasitol* 87:617–626
- Schofield L, Novakovic S, Gerold P, Schwarz RT, McConville MJ, Tachado SD (1996) Glycosylphosphatidylinositol toxin of *Plasmodium* up-regulates intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin expression in vascular endothelial cells and increases leukocyte and parasite cytoadherence via tyrosine kinase-dependent signal transduction. *J Immunol* 156:1886–1896
- Schofield L, McConville MJ, Hansen D, Campbell AS, Fraser-Reid B, Grusby MJ, Tachado SD (1999) CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. *Science* 283:225–229

- Schofield L, Hewitt MC, Evans K, Siomos MA, Seeberger PH (2002) Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. *Nature* 418:785–789
- Schwarzer E, Kuhn H, Valente E, Arese P (2003) Malaria-parasitized erythrocytes and hemozoin nonenzymatically generate large amounts of hydroxy fatty acids that inhibit monocyte functions. *Blood* 101:722–728
- Scragg IG, Hensmann M, Bate CA, Kwiatkowski D (1999) Early cytokine induction by *Plasmodium falciparum* is not a classical endotoxin-like process. *Eur J Immunol* 29:2636–2644
- Seeberger PH, Soucy RL, Kwon YU, Snyder DA, Kanemitsu T (2004) A convergent, versatile route to two synthetic conjugate anti-toxin malaria vaccines. *Chem Commun (Camb)* 1706–1707
- Serirom S, Raharjo WH, Chotivanich K, Loareesuwan S, Kubes P, Ho M (2003) Anti-adhesive effect of nitric oxide on *Plasmodium falciparum* cytoadherence under flow. *Am J Pathol* 162:1651–1660
- Shams-Eldin H, Azzouz N, Kedees MH, Orlean P, Kinoshita T, Schwarz RT (2002) The GPII homologue from *Plasmodium falciparum* complements a *Saccharomyces cerevisiae* GPII anchoring mutant. *Mol Biochem Parasitol* 120:73–81
- Sherry BA, Alava G, Tracey KJ, Martiney J, Cerami A, Slater AF (1995) Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF, MIP-1 alpha, and MIP-1 beta) in vitro, and altered thermoregulation in vivo. *J Inflamm* 45:85–96
- Sieling PA, Chatterjee D, Porcelli SA, Prigozy TI, Mazzaccaro RJ, Soriano T, Bloom BR, Brenner MB, Kronenberg M, Brennan PJ, . (1995) CD1-restricted T cell recognition of microbial lipoglycan antigens. *Science* 269:227–230
- Singh RP, Kashiwamura S, Rao P, Okamura H, Mukherjee A, Chauhan VS (2002) The role of IL-18 in blood-stage immunity against murine malaria *Plasmodium yoelii* 265 and *Plasmodium berghei* ANKA. *J Immunol* 168:4674–4681
- Sinton JA (1938) Immunity or tolerance in malarial infections. *Proc R Soc Med* 31:1298–1302
- Smith T, Genton B, Baea K, Gibson N, Taime J, Narara A, Al Yaman F, Beck HP, Hii J, Alpers M (1994) Relationships between *Plasmodium falciparum* infection and morbidity in a highly endemic area. *Parasitology* 109:539–549
- Smith T, Felger I, Tanner M, Beck HP (1999) Premunition in *Plasmodium falciparum* infection: insights from the epidemiology of multiple infections. *Trans R Soc Trop Med Hyg* 93:S59–S64
- Smith TK, Sharma DK, Crossman A, Dix A, Brimacombe JS, Ferguson MA (1997) Parasite and mammalian GPI biosynthetic pathways can be distinguished using synthetic substrate analogues. *EMBO J* 16:6667–6675
- Smith TK, Sharma DK, Crossman A, Brimacombe JS, Ferguson MA (1999) Selective inhibitors of the glycosylphosphatidylinositol biosynthetic pathway of *Trypanosoma brucei*. *EMBO J* 18:5922–5930
- Smith TK, Crossman A, Borissow CN, Paterson MJ, Dix A, Brimacombe JS, Ferguson MA (2001) Specificity of GlcNAc-PI de-N-acetylase of GPI biosynthesis and synthesis of parasite-specific suicide substrate inhibitors. *EMBO J* 20:3322–3332



- Smith TK, Gerold P, Crossman A, Paterson MJ, Borissow CN, Brimacombe JS, Ferguson MA, Schwarz RT (2002) Substrate specificity of the *Plasmodium falciparum* glycosylphosphatidylinositol biosynthetic pathway and inhibition by species-specific suicide substrates. *Biochemistry* 41:12395–12406
- Smith TK, Crossman A, Brimacombe JS, Ferguson MA (2004) Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness. *EMBO J* 23:4701–4708
- Snow RW, Marsh K (1998) New insights into the epidemiology of malaria relevant for disease control. *Br Med Bull* 54:293–309
- Sowunmi A (1995) Body temperature and malaria parasitaemia in rural African children. *East Afr Med J* 72:427–430
- Stevenson MM, Riley EM (2004) Innate immunity to malaria. *Nat Rev Immunol* 4:169–180
- Suguitan AL, Jr., Gowda DC, Fouda G, Thuita L, Zhou A, Djokam R, Metenou S, Leke RG, Taylor DW (2004) Lack of an association between antibodies to *Plasmodium falciparum* glycosylphosphatidylinositols and malaria-associated placental changes in Cameroonian women with preterm and full-term deliveries. *Infect Immun* 72:5267–5273
- Sutterlin C, Horvath A, Gerold P, Schwarz RT, Wang Y, Dreyfuss M, Riezman H (1997) Identification of a species-specific inhibitor of glycosylphosphatidylinositol synthesis. *EMBO J* 16:6374–6383
- Tachado SD, Gerold P, McConville MJ, Baldwin T, Quilici D, Schwarz RT, Schofield L (1996) Glycosylphosphatidylinositol toxin of *Plasmodium* induces nitric oxide synthase expression in macrophages and vascular endothelial cells by a protein tyrosine kinase-dependent and protein kinase C-dependent signaling pathway. *J Immunol* 156:1897–1907
- Tachado SD, Gerold P, Schwarz R, Novakovic S, McConville M, Schofield L (1997) Signal transduction in macrophages by glycosylphosphatidylinositols of *Plasmodium*, *Trypanosoma*, and *Leishmania*: activation of protein tyrosine kinases and protein kinase C by inositolglycan and diacylglycerol moieties. *Proc Natl Acad Sci U S A* 94:4022–4027
- Takeda K, Takeuchi O, Akira S (2002) Recognition of lipopeptides by Toll-like receptors. *J Endotoxin Res* 8:459–463
- Taramelli D, Basilico N, Pagani E, Grande R, Monti D, Ghione M, Olliaro P (1995) The heme moiety of malaria pigment (beta-hematin) mediates the inhibition of nitric oxide and tumor necrosis factor-alpha production by lipopolysaccharide-stimulated macrophages. *Exp Parasitol* 81:501–511
- Taramelli D, Recalcati S, Basilico N, Olliaro P, Cairo G (2000) Macrophage preconditioning with synthetic malaria pigment reduces cytokine production via heme iron-dependent oxidative stress. *Lab Invest* 80:1781–1788
- Taron BW, Colussi PA, Wiedman JM, Orlean P, Taron CH (2004) Human Smp3p adds a fourth mannose to yeast and human glycosylphosphatidylinositol precursors in vivo. *J Biol Chem* 279:36083–36092
- Taylor RR, Allen SJ, Greenwood BM, Riley EM (1998) IgG3 antibodies to *Plasmodium falciparum* merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. *Am J Trop Med Hyg* 58:406–413



- Turrini F, Giribaldi G, Valente E, Arese P (1997) *Mycoplasma* contamination of *Plasmodium* cultures—a case of parasite parasitism. *Parasitol Today* 13:367–368
- Vadas P, Taylor TE, Chimsuku L, Goldring D, Stefanski E, Pruzanski W, Molyneux ME (1993) Increased serum phospholipase A2 activity in Malawian children with falciparum malaria. *Am J Trop Med Hyg* 49:455–9
- van der Poll T, Coyle SM, Moldawer LL, Lowry SF (1996) Changes in endotoxin-induced cytokine production by whole blood after in vivo exposure of normal humans to endotoxin. *J Infect Dis* 174:1356–1360
- van der Poll T, van Deventer SJH (1999) Endotoxemia in healthy subjects as a human model of inflammation. *1st*:335–357
- van Hensbroek MB, Palmer A, Onyiorah E, Schneider G, Jaffar S, Dolan G, Memming H, Frenkel J, Enwere G, Bennett S, Kwiatkowski D, Greenwood B (1996) The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. *J Infect Dis* 174:1091–1097
- Vijaykumar M, Naik RS, Gowda DC (2001) Plasmodium falciparum Glycosylphosphatidylinositol-induced TNF-alpha Secretion by Macrophages Is Mediated without Membrane Insertion or Endocytosis. *J Biol Chem* 276:6909–6912
- Wahlstrom K, Bellingham J, Rodriguez JL, West MA (1999) Inhibitory kappaB-alpha control of nuclear factor-kappaB is dysregulated in endotoxin tolerant macrophages. *Shock* 11:242–247
- Wattavidanage J, Carter R, Perera KL, Munasingha A, Bandara S, McGuinness D, Wickramasinghe AR, Alles HK, Mendis KN, Premawansa S (1999) TNFalpha\*2 marks high risk of severe disease during Plasmodium falciparum malaria and other infections in Sri Lankans. *Clin Exp Immunol* 115:350–355
- West MA, Heagy W (2002) Endotoxin tolerance: A review. *Crit Care Med* 30:S64–S73
- Wood P, Elliott T (1998) Glycan-regulated antigen processing of a protein in the endoplasmic reticulum can uncover cryptic cytotoxic T cell epitopes. *J Exp Med* 188:773–778
- Xiao L, Patterson PS, Yang C, Lal AA (1999) Role of eicosanoids in the pathogenesis of murine cerebral malaria. *Am J Trop Med Hyg* 60:668–673
- Zhu J, Krishnegowda G, Gowda DC (2004) Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols (GPIs) of Plasmodium falciparum: The requirement of ERK, p38, JNK and NF-kappa B pathways for the expression of proinflammatory cytokines and nitric oxide. *J Biol Chem* Dec 15: Epub ahead of print
- Ziegler-Heitbrock HW, Wedel A, Schraut W, Strobel M, Wendelgass P, Sternsdorf T, Bauerle PA, Haas JG, Riethmuller G (1994) Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. *J Biol Chem* 269:17001–17004
- Zingarelli B, Halushka PV, Caputi AP, Cook JA (1995) Increased nitric oxide synthesis during the development of endotoxin tolerance. *Shock* 3:102–108
- Zingarelli B, Hake PW, Cook JA (2002) Inducible nitric oxide synthase is not required in the development of endotoxin tolerance in mice. *Shock* 17:478–484



<http://www.springer.com/978-3-540-25718-9>

Immunology and Immunopathogenesis of Malaria  
2005, XI, 234 p., Hardcover  
ISBN: 978-3-540-25718-9